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Background: The advent of novel agents (IMiDs-Thalidomide and Lenalidomide and 
Bortezomib) in the therapy of Multiple Myeloma (MM) has resulted in superior response rates 
and progression free survival (PFS). As there is only meagre data from India, we retrospectively 
analyzed the role of Thalidomide-Dexamethasone (TD) as initial therapy in newly diagnosed 
MM.  
Aims and Objectives of the study: 1) To retrospectively analyze the response rate, 
progression free survival (PFS) and overall survival (OS) of newly diagnosed multiple myeloma 
cases treated with Thalidomide-Dexamethasone (TD) as induction therapy. 2) To analyze impact 
of Autologous Stem Cell Transplantation (ASCT) and Thalidomide maintenance in prolonging 
the PFS and OS. 
Methodology: All patients newly diagnosed to have MM and initiated on TD as initial therapy 
in the Department of Haematology, between March 2004 and September 2012 were analyzed.  
Results: A total of 242 patients with a median age of 54 yrs (range 21 to 80yrs), with a male: 
female ratio of 2.5 was initiated on TD. At diagnosis anaemia (Hb <10 g/dl) was seen in 59.1%, 
bone involvement was seen in 57.4%, renal failure (Sr.Creat ≥ 2mg/dl) was seen in 21.1%, 
hypercalcemia (Corrected Sr.Calcium ≥ 10.5 mg/dl) was seen in 19.8% and plasmacytoma was 
seen in 23.6%. One patient with past history of MGUS and 5 patients with solitary 
plasmacytoma had progressed to MM. The proportion of patients according to the Durie Salmon 
staging (DSS) in the 242 patients was 12.8%, 35.5% and 51.7% for DSS I, II and III 
respectively. The proportion of patients according to the ISS categorisation of the 209 patients 
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was 25.4%, 32.5% and 42.1% for ISS I, II and III respectively. Median number of cycles of TD 
was 7 (range-1 to 27) and the median dose of Thalidomide was 200mg OD (range-50mg to 
400mg OD). The median dose of Dexamethasone was 40 mg OD (Range: 8 – 40 mg OD). 
Aspirin was given as DVT prophylaxis in 217 patients and one patient received Sintrom as he 
had deep vein thrombosis (DVT) at diagnosis. One patient was continued on Clopidogrel, which 
was initiated after a cerebrovascular event in the past. Seventeen patients were excluded for 
analysis and considered lost to follow up as they did not have response assessment after initiation 
of TD. The overall response to TD was 80.4%, with a complete response unconfirmed + 
complete response (CRu+CR) rate of 8.8%, very good partial response (VGPR) rate of  31.1%, 
partial response (PR) rate of  40.4% and no response (NR) rate of 19.6%. The median time to 
respond was 3 months (range: 1-13 months). ASCT was done in 29 patients, 13 patients upfront 
post TD induction and 16 patients after salvage therapy after relapse/progressive disease. 
Thalidomide maintenance was initiated post response to TD in for 49 patients. In one hundred 
and nineteen patients responding to TD did not have any further therapy. The progression free 
survival (PFS) at 36 months in the ASCT group, Thalidomide maintenance group and no 
treatment group was 83.3%, 55.1% and 14.7% respectively (p=0.0000). However the overall 
survival (OS) was not statistically significant among these groups. The 3yr The PFS and OS of 
the entire cohort of patient was 26.3% and 76.9% respectively. 
Conclusion: In this first large series from India, comprehensively analyzing outcome of 
patients with newly diagnosed MM treated with TD, the response to treatment was similar to 
those reported in the literature from other population. ASCT and Thalidomide maintenance 
therapy significantly improved the PFS. 




Multiple myeloma (MM) is a malignant disorder characterized by a single clone of mature 
plasma cells producing a monoclonal protein.(1) It accounts for 14% of all hematological 
malignancies.(2) It usually evolves from an asymptomatic stage of monoclonal gamopathy of 
undetermined significance (MGUS).(3)  
Therapy in multiple myeloma is indicated only if there is related organ or tissue impairment 
(ROTI) in the form of anaemia, renal failure, hypercalcemia or bone lesion caused by the 
proliferating plasma cells.(4) The therapy of MM has evolved from Melphalan-Prednisolone 
(MP)(5) in the 1960s to Autologous stem cell transplantation (ASCT) in the 1980s.(6) VAD 
(Vincristine, Adriamycin and Dexamethasone) replaced MP as induction therapy prior to ASCT, 
due to the stem cell toxicity of the Melphalan. VAD followed by ASCT remained the standard of 
care until the advent of the novel agents.(7)(8) The novel agent, such as the immunomodulatory 
drugs (IMiDs) - Thalidomide and Lenalidomide and the proteosome inhibitor Bortezomib,   has 
markedly impacted the therapy of MM in the last decade.(9) Thalidomide was the first novel 
agent used in the therapy of relapsed/refractory MM yielding a response rate of about 30%.(10) 
Subsequently the addition of Dexamethasone to Thalidomide improved the response rates to 
50% in relapsed/ refractory disease. This led to a number of phase II studies using Thalidomide 
and Dexamethasone (TD) as initial therapy for the treatment of newly diagnosed MM. The 
overall response rate of TD was 65%, which was similar to VAD chemotherapy.(11) With the 
ease of orally administered therapy and similar efficacy of TD compared to VAD chemotherapy, 
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which requires a central line for infusion of drugs, has complications related to the line and the 
hematological toxicity, TD replaced VAD as initial therapy of MM in the early part of the last 
decade. Thalidomide has also been used as maintenance therapy post induction and post ASCT. 
There is evidence of progression free survival benefit(12) with In addition Thalidomide 
maintenance, however there is conflicting data regarding overall survival benefit.(12)(13) Data 
on long term outcome of TD is not mature and there is no published literature on the use of TD 
in newly diagnosed MM from India. In this study we retrospectively analyzed the response rates, 
progression free survival and overall survival of TD in the treatment of newly diagnosed MM 
and the benefit of Thalidomide maintenance and ASCT post induction.        
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 Review of Literature 
Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 
14% of all hematologialc cancers.(2) MM is characterized by terminally differentiated plasma 
cells, infiltration of the bone marrow by plasma cells, and the presence of a monoclonal 
Immunoglobulin or Immunoglobulin fragment in the serum and/or urine.(1) It usually is 
associated with one or more of the following: osteolytic lesions of the bone, anemia, renal failure 
and hypercalcemia.(14) Myeloma consistently evolves from an asymptomatic stage of clonal 
plasma cell proliferation termed “monoclonal gammopathy of undetermined significance” 
(MGUS).(3) MGUS is present in more than 3% of the population above the age of 50 and 
progresses to myeloma or related malignancy at a rate of 1% per year.(15),(16) A  more 
advanced stage, “smoldering multiple myeloma”(SMM), is clinically recognized in some 
patients. The risk of SMM progressing to active myeloma is 10% in the first 5 years, which 
decreases to 3% between 5 - 10 years and 1% between 10 – 20 years.(17)  
The estimated incidence of myeloma and death due to myeloma in US in 2010 was 20,180 and 
10,650, respectively.(2) The annual incidence of myeloma, age-adjusted to the 2000 US 
population, is 4.3 per 100 000.(18) In Europe, the incidence of MM is 6.0 per 100,000 per 
year.(19) The incidence of myeloma was lower(1-2 per 100,000 per year) in Japan and China, 
similar to the Asians living in US.(2),(20) The annual incidence of myeloma in India is between 
1.28 per 100000 per year.(21) The median age at diagnosis is between 60 - 70 years.(19),(22) 
There is a slight male predominance with 55% of the affected individuals being males.(2) The 
prevalence of MM is steadily increasing in view of the improvement in therapy over the last 
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decade.(9)(23) Using the data between the period 1973-2005 from the   database of the 
Surveillance, Epidemiology, and End Results (SEER) Program, the projected 5-and 10-year 
relative survival expectations of multiple myeloma patients in the US diagnosed between 2006-
2010 below 45 years of age is 68.0% and 55.3% respectively. This exceeds the most up-to-date 
estimates obtained from traditional cohort and period analysis by 15.5 and 7.0 percent units 
respectively for 5 yr relative survival and by 19.7 and 7.4 percent units respectively for ten-year 
relative survival.(24) 
History 
The first description of Multiple myeloma was published in 1844 by Solly.(Figure – 1 and 2) He 
described a 39 year old female with fatigue and bone pains due to multiple fractures and named 
the disease as mollities ossium.(25) Mr. Thomas Alexander McBean, 45 years old male was the 
first best known case of Multiple myeloma.(26) He also had fatigue, multiple fractures and noted 
that his “body linen was stiffened by his urine.” At autopsy bones were soft, brittle, readily 
fractured and a “gelatiniform substance of a blood-red colour and unctuous feel” was found in 
the bones. The term ‘multiple myeloma’ was first introduced by J.von Rustizky in 1873, after 
finding eight separate tumor masses in the bones at autopsy of a patient. John Dalrymple 
examined the bone marrow of McBean and gave the first histological description of plasma cells, 
which were round or oval shaped, 1.5 – 2 times as large as an average blood cell and contained 1 
or 2 nuclei and a bright-colored nucleolus. Geschickter and Copeland emphasized the presence 
of pathologic fractures, urine BJP, anemia, and chronic renal disease in MM based on 412 cases 
of MM found in the literature from 1848 to 1928.(27)  
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Though Waldeyer first used the term “plasma cells” in 1875, the accurate description of 
perinuclear hoff and eccentric nucleus with blocked chromatin in plasma cells was by Ramon 
Cajal in 1890.(26) Wright demonstrated plasma cells in normal bone marrow and suggested that 
Myeloma is a neoplasm originating from the plasma cells.(26) Sternal bone-marrow aspiration 
was reported by Arinkin in 1927 and facilitated the diagnosis of MM.(26) 
Thomas Watson, William Macintyre and Bence Jones first described in 1845 the characteristics 
of the urine protein found in a patient with MM. The addition of nitric acid to the urine produced 
a precipitate that was re-dissolved on heating and reappeared on cooling. Fleischer was the first 
to use the term ‘Bence Jones Protein’ in 1880.(26) Two types of BJP were identified using 
antisera prepared by immunizing rabbits with injection of BJP. Korngold and Lipari 
demonstrated that antisera to BJP also reacted against myeloma protein and as a tribute to them, 
the two types of BJP were named kappa and lambda.(28) It was not untill hundred and seventeen 
years after the first description of urine BJP, Edelman & Gally in 1962 demonstrated that the 
urine BJP and the light chains prepared from an IgG monoclonal protein of the same patient had 
an identical amino-acid composition. These light chains precipitated when heated to between 
40˚C and 60˚C, dissolved on boiling and re-precipitated with cooling to between 40˚C and 60˚C, 
which is identical with the heat properties of BJP.(29)  
In 1928 Perlzweig et al described hyperproteinemia in MM.(27) Tiselius separated serum 
proteins into three components and designated them as alpha, beta, and gamma.(30) Tiselius and 
Kabat demonstrated that the antibody activity resides in the gamma globulin fraction.(31) The 
characteristic of multiple myeloma, the tall, narrow-based “church spire” peak was recognized in 
1939.(32)  The moving-field electrophoresis, a cumbersome and a daylong procedure was 
replaced in 1951 by electrophoresis using filter paper as a support.(33) Cellulose acetate replaced 
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filter paper and currently agarose gel or capillary electrophoresis is used for serum and urine 
protein electrophoresis. In 1953 Grabar and Williams described Immunoelectrophoresis (34) and  
11 years later, Wilson introduced immunofixation electrophoresis.(35) 
Jan Waldenstrom introduced the concept of monoclonal vs. polyclonal gammopathies in 
1961.(36) He considered the broad band in hypergammaglobulinemia as a polyclonal increase in 
globulins. It is important to distinguish monoclonal from polyclonal gammopathies, because 
patients with a monoclonal gammopathy either have a neoplastic process or may develop a 
malignancy subsequently. Many of his patients had multiple myeloma or macroglobulinemia, 
while others had no evidence of malignancy and he considered them to have “essential 
hypergammaglobulinemia” or a “benign monoclonal protein”. With our present understanding of 
plasma cell dyscrasias, the preferred terminology today is Monoclonal Gammopathy of 
Undetermined Significance (MGUS), as multiple myeloma, macroglobulinemia, light-chain 
(AL) amyloidosis, or a related disorder may subsequently ensue.(15) 
Any protein that migrated to the γ mobility region in the electrophoretic pattern was termed 
`gamma globulin' and are now referred to as immunoglobulins IgG, IgA, IgM, IgD and IgE. 
Etiology 
Familial clustering of MM has been described. MM presents at an early age in familial cases and 
there is an increased incidence of other malignancies, both hematological and solid tumors in 
these families.(37)(38) In a study in Sweeden the MM cases were found to be clustered in 
families with MM, non Hodgkin lymphoma and chronic lymphocytic leukaemia. There was an 
autosomal dominant pattern of incidence of familial MM.(39) 
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Environmental exposure to ionizing radiation, farming pesticides, or possibly petrochemicals 
also increases the risk of MM. There is an increased incidence of multiple myeloma in persons 
with rheumatoid arthritis or body mass index of more than 30 kg/ m2 (40). In majority of the 
cases there is no obvious etiology. 
Pathophysiology 
Immunoglobulin molecules contain two linked heavy chains, with one light chain attached to 
each. Normally, plasma cells produce immunoglobulins to fight infection. However, monoclonal 
myeloma plasma cells proliferate and overproduce M protein (abnormal IgG, IgM, or IgA, or 
rarely IgE or IgD). Multiple myeloma cells also produce abnormal light chain proteins (κ or λ), 
cytokines that stimulate osteoclasts and suppress osteoblasts, and angiogenesis factors that 
promote new blood vessel formation. Therefore, the multiple myeloma process leads to an 
excessive M protein level, which causes hyper viscosity; light chain proteins that cause end-
organ damage, especially in the kidneys; and invasive bone lesions that cause bone pain, 
osteoporosis, and hypercalcemia. Bone marrow invasion leads to anemia, and immunologic 
alterations contribute to recurrent infections. 
Clinical features 
Presenting clinical features include symptoms of 
 Bone disease  
 Impaired renal function  
 Anemia  
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 Hypercalcemia  
 Recurrent or persistent bacterial infection  
 Hyperviscosity  
 
Most patients with MM initially present with unexplained backache or bone pain. Most patients 
have multiple lytic skeletal lesions involving the long bones, ribs, skull, and pelvis. Pathologic 
fracture is the presenting symptom in 26 to 34% of patients.(41)(42) Vertebral compression 
fractures can lead to weakness and paresthesias in the lower extremities. They can also present 
with features of hypercalcemia such as anorexia, nausea, somnolence, and polydipsia. Weakness 
and malaise are manifestation of multiple myeloma associated with anemia. Impaired 
immunoglobulin production and leukopenia lead to recurrent infections, usually from 
encapsulated organisms. Pneumonia is the most common infection. Weight loss occurs in less 
than 25% of patients. Unexplained fever is a rare presentation. The incidence of presenting 
symptoms in multiple myeloma are as given in table 1.(41)(42) Hypercalcaemia, spinal cord 
compression and renal failure are medical emergencies requiring immediate investigation and 
treatment. Rare presentations include soft tissue or solitary skeletal plasmacytomas, hyper 
viscosity-induced arterial infarctions or venous thrombosis, and concomitant amyloidosis with 
gastrointestinal symptoms, peripheral neuropathy, or cardiomegaly. 
Serum protein electrophoresis revealed a localized band in 82% of patients. Urine BJP was found 
in the urine in 78% of cases. When serum free light chain and immunofixation electrophoresis 
was used, a monoclonal protein was demonstrable in at least 97% of cases. Nonsecretory 
myeloma was recognized in 3%, whereas light-chain myeloma was present in 20% of MM. 
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Conventional radiographs showed an abnormality in 79%. The plasma cell labeling index was ≥ 
1% in 34% of patients.(41) M band consisted of IgG isotype in 58-70%, IgA isotype in 24%, 
light-chain isotype in 11%, IgD isotype in 3%, and biclonal or other isotype in 2-5%.(21)(22) 
 
Investigation and diagnosis  
Investigation of a patient with suspected myeloma should include the screening tests, followed 
by further tests to confirm the diagnosis.(43) 
Screening tests: 






Electrophoresis of serum and concentrated urine  
Quantification of non-isotypic immunoglobulins 
X-ray of symptomatic areas  
Tests to establish diagnosis 
Bone marrow aspirate + trephine biopsy with plasma cell phenotyping 
Immunofixation of serum and urine 
Skeletal survey 
Tests to estimate tumor burden and prognosis  
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Fluorescence in situ hybridisation (FISH) analysis  
Quantification of monoclonal protein in serum and urine  
Albumin  
Β2-microglobulin  
Skeletal survey  
Tests to assess myeloma-related organ impairment (ROTI)  
FBC  
Serum urea and creatinine  
Creatinine clearance (measured or calculated)  
Calcium  
Albumin  
Tissue biopsy (or fat pad aspirate) for amyloid (if suspected)  
Quantification of non-isotypic immunoglobulins  
Skeletal survey  
Special tests indicated in some patients  
Serum free light chain assay in oligo-secretory, light chain only and non-secretory disease  
Magnetic resonance imaging (MRI)  
Computerised tomography (CT) scan   
Quantification of serum M-protein should be performed by densitometry of the monoclonal peak 
on electrophoresis; immunochemical measurement of total immunoglobulin isotype level can 
also be used.(43) Quantification of urinary total protein and light chain excretion can be 
performed directly on a 24-hour urine collection or calculated on a random urine sample in 
relation to the urine creatinine.(43) The serum free light chain assay is very useful for the 
 17
diagnosis and monitoring of light chain only myeloma (44) and in patients with oligo secretory / 
non-secretory MM.(45) In renal impairment the half life and thus the serum concentration of 
SFLC can increase tenfold and there is often an increased kappa: lambda ratio.(46) A bone 
marrow (BM) assessment should be done for confirmation of the diagnosis of myeloma. An 
adequate trephine biopsy of at least 20 mm in length is recommended in the diagnosis of MM, as 
it provides a better assessment of the extent of marrow infiltration than aspirate smears.(47)(48)  
Diagnostic criteria and differential diagnosis  
A diagnosis of myeloma should be made using the International Myeloma Working Group 
(IMWG) criteria proposed in 2003,(4) which are detailed in Table 2. It is necessary to 
differentiated between MGUS and asymptomatic myeloma from symptomatic myeloma, since 
only symptomatic myeloma needs treatment. Difference between an asymptomatic myeloma and 
symptomatic myeloma is the presence of related organ or tissue impairment. (Table-3)  
 
Prognostication 
Age is an independent prognostic factor in Multiple myeloma and, importantly, provides a major 
criterion by which patients can be considered eligible to tolerate high-dose therapy (HDT) with 
autologous hematopoietic stem cell transplantation (ASCT).(49) In a study by the International 
Myeloma working group of 10579 cases, age less than 50 years had an overall survival 




Durie and Salmon staging system (DSS)(50) and  International staging system (ISS)(22) have 
been used for the prognostication of the disease. DSS is based on the assessment of tumor 
burden. ISS is based on two easily available laboratory parameters (Serum albumin and 
β2microglobulin). ISS is more widely used because of the ease of risk assessment and its 
prognostic significance.  
Cytogenetic abnormalities which confer an adverse prognosis are t (4;14) and t(14;16) or 
deletion of chromosome 17, del(17p), by fluorescence in situ hybridization and monosomy or 
del(13q) or hypodiploidy by metaphase cytogenetics. These cytogenetic abnormalities are 
present at diagnosis in 25% of patients.(51) Updated Multiple myeloma mSMART consensus 
guidelines have classified newly diagnosed MM patients into three risk groups. High risk group 
is defined by the presence of del 17p, t (14; 16), t (14; 20) and high risk signature in the gene 
expression profiling. Intermediate risk group is defined by the presence of t (4; 14) by FISH, del 
13 or hypodiploidy by metaphase cytogenetics or PCLI >3%. Patients with t (4; 14) is considered 
to have high risk if associated with high β2microglobulin (≥4) and anaemia (≤10 g/dl). Standard 
risk is defined by all other abnormalities including hyperdiploidy, t(11;14) and t(6;14).(52) 
Treatment 
The treatment of MM has much evolved from rhubarb pill, infusion of orange peel, phlebotomy 
and application of leeches in 1840s.(26) Urethane was the first alkylating agent used in the 
treatment of MM by Alwall in 1947.(53) Subsequently Sarcolysin (Melphalan: L-Phenylalanine 
mustard) was used by Blokhin et al in 1953.(54) Mass et.al., demonstrated the efficacy of single 
agent Prednisolone in the treatment of MM in a placebo controlled trial, although there was no 
survival benefit compared to placebo.(55) Alternate day dosing of Prednisolone was shown to 
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have efficacy with reduced toxicity.(56) Various combinational chemotherapies were tried in an 
attempt to treat MM. The classical regimen of Melphalan-Prednisolone(MP) was reported by 
Alexanian et al, in a randomized trial of 183 patients of MM, in which MP was shown to have a 
6 months longer survival compared with single agent Melphalan.(5) Standard induction therapies 
prior to the advent of novel agents included VAD (vincristine, doxorubicin, dexamethasone), 
DVD (vincristine, liposomal doxorubicin and dexamethasone) and high-dose dexamethasone 
with response rates between 40–61%.(57)(58)(59)(60) The CR rates with these regimens are 
typically low in the range of 3% to 13%. Meta-analysis of individual data of 6633 persons from 
27 randomized trials showed a significantly higher response rates with combination 
chemotherapy than with MP (60.0% v 53.2%; P < .00001). However there were no significant 
differences in the response duration or overall survival.(61) Hence MP remained as the mainstay 
of MM therapy, until the advent of autologous stem cell transplantation.  
The concept of high dose therapy (HDT) evolved in the early 1980s. The first report of HDT 
using Melphalan 100 to 140 mg/m2 was reported in 1983 by McElwain and Powles (62), the 
effectiveness of such an approach was confirmed in a subsequent larger study of 63 patients.(63) 
Autologous stem cell support to overcome the prolonged duration of neutropenia of HDT was 
proposed by Barlogie et al(6). The Intergroupe Francophone du Mye´lome (IFM) group 
conducted a randomized trial showing the superiority of HDT with autologous stem cell support 
compared with conventional chemotherapy (CC).(7) This study showed a better progression free 
survival (PFS) and overall survival (OS) in the HDT group compared to the conventional 
chemotherapy group.  This result was confirmed in the Medical Research Council VII study 
involving 400 patients.(8) These two studies established HDT with stem cell support as the 
standard of care for patients with Multiple myeloma younger than 65 years of age. However 
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other randomized trials did not show a better OS in the HDT arm compared to the CC 
arm.(64)(65)(66) Systematic review and meta-analysis of randomized trials showed that ASCT 
had an impact on the PFS, but not on the OS.(67) The reason for the non significant difference in 
the OS could be attributable to the availability of better salvage regimens and ASCT after 
relapse. 
In the IFM 90 trial the impact of achieving CR or at least very good partial remission (VGPR) on 
the OS was shown. Patients who achieved a CR or VGPR had a longer OS than patients who 
achieved only partial remission (PR). The influence of the depth of response pre and post 
HDT/ASCT on both EFS and OS was also demonstrated in a study by Lahuretta JJ et.al.(68)     
The association between complete response after HDT/ASCT and better OS and PFS was shown 
in a meta-analysis of 21 trial involving 4990 patients.(69)  
The ASCT trials used either Melphalan or Total Body Irradiation (TBI) in addition to Melphalan. 
In an IFM trial Melphalan 200mg/m2 was compared with Melphalan 140mg/m2 + 8 Gy of TBI 
and showed that the event free survival was similar in both groups and the OS was better in the 
Melphalan 200mg/m2 group.(70) This established Melphalan 200mg/m2 as the standard 
conditioning regimen. Further intensification of therapy was tried using double ASCT. The IFM 
94 trial was conducted with the objective of identifying the group of patients, who will benefit 
from double ASCT.(71) The response to first ASCT, was the only parameter that predicted the 
benefit of double ASCT. Patients with less than VGPR after the first ASCT had a longer OS in 
the double-ASCT arm, whereas patients achieving CR or VGPR after the first ASCT had similar 
OS with or without the second ASCT. 
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Over the last decade, the survival of patients with newly diagnosed MM, particularly those 
younger than 60 years, has significantly improved.(9) The widespread use of ASCT and the 
introduction into clinical practice of the novel agents immunomodulatory derivatives (IMiDs), 
thalidomide and lenalidomide and the proteasome inhibitor bortezomib have significantly 
contributed to major advances in the therapy of and its prognosis.(72)(23)  
Thalidomide (a-Naphthalimido-glutarimide) is a synthetic derivative of glutamic acid, which was 
infamous for causing birth defects when used as an antiemetic in pregnancy in the late 1950s and 
early 1960s. Despite its withdrawal from most markets at this point, it was serendipitously found 
to be effective in the treatment of erythema nodosum leprosum. Thalidomide has unique 
immunomodulatory, anti-inflammatory and antiangiogenic properties. The main mechanisms 
proposed to explain its antimyeloma activity are (73) (74) 
(i) immunomodulatory effects on cytokine production and T-cell activation;  
(ii) inhibition of cell adhesion;  
(iii)antiangiogenic effects; and  
(iv) direct inhibition of tumor growth and survival 
(v) NF-kappa B suppression 
Thalidomide was first used in the treatment of relapsed MM in 1999.(75) A systematic review of 
phase II trials using single agent Thalidomide in relapsed or refractory MM involving 1674 
patients showed an overall response of 29.4% and a median OS of 14 months.(10) The dose of 
Thalidomide used ranged between 50 mg/day to 800 mg/day.(10) In a prospective randomized 
study, 400 patients with relapsed or refractory MM were treated with thalidomide at a dose of 
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100 mg/day or 400 mg/day, and the two dosage had no significant difference in 1-year OS (73% 
vs. 69%, respectively).(76)  
Preclinical studies had shown that both thalidomide and lenalidomide (IMiDs) potentiate the 
activity of dexamethasone, providing the rational for the combination therapy of IMiDs with 
Dexamethasone.(77) Subsequently trials established the superiority of Thalidomide-
Dexamethasone combination therapy in relapsed/refractory MM compared to single agent 
Thalidomide(Response rate 50% vs. 30%).(78) These studies provided the rationale for 
subsequent phase 2 and 3 trials investigating the role of this regimen in patients with newly 
diagnosed MM.   
In 2005, a retrospective case-matched study by Cavo et.al., demonstrated the superior rate and 
depth of response affected by TD compared with VAD as induction therapy in preparation for 
ASCT,(79) This finding was confirmed in a subsequent phase 3 study.(80) Phase II trials of TD 
in newly diagnosed MM showed a response of 65% to 70%, similar to VAD 
chemotherapy.(81)(82)(83) Moreover TD has the convenience of oral administration and no 
cardiotoxicity or alopecia seen with VAD. Based on the results of a randomized study showing a 
higher response rate with TD compared with high-dose dexamethasone(11), the United States 
Food and Drug Administration granted accelerated approval for TD in patients with newly 
diagnosed MM. As a result, over the past years, TD has emerged as one of the most commonly 
used induction regimens in the United States and European countries (European Union).   
In the ECOG E1A00 trial, TD demonstrated superior response rates compared to dexamethasone 
(63% vs. 41%, P = 0·0017) following 4 months of induction therapy.(11) In the MM003 trial, 
TD significantly prolonged time to progression (TTP) compared with dexamethasone alone 
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(median 22·6 months vs. 6·5 months, P < 0·001); however, no conclusion regarding survival 
could be drawn from this study as it was not powered to compare survival.(84) In a French trial 
comparing TD with VAD, the improvement in ≥VGPR rate achieved with TD versus VAD post-
induction did not translate to an improvement in post-transplant ≥VGPR for TD over VAD; 
There was no survival benefit.(80)  
In all studies, TD and TAD were superior to VAD in terms of overall response and VGPR rates 
(Table 3). However, the thalidomide-based regimens did not increase the CR rate prior to ASCT, 
which remained at a very low < 10%. Post-ASCT results were analyzed in two trials: Although 
VGPR rates with TD and VAD were similar; VGPR rates were superior with TAD as compared 
with VAD (Table 3). The drawback of thalidomide therapy includes a high incidence of deep 
vein thrombosis, up to 26% and peripheral neuropathy. (83) The role of other novel agents in the 
therapy of MM is beyond the scope of this study. 
Maintenance therapy 
Maintenance therapy is given after the patient achieves a response to an initial therapy of 
myeloma with the goal of extending the PFS and OS, while maintaining a good quality of life.  
Several randomized studies shown a PFS benefit with thalidomide as single agent or combined 
with prednisone as maintenance therapy after ASCT.(85)(86)(87)(88)(Table 4). In 2 of these 
studies, OS was extended in the thalidomide arm.(87)(88) This advantage was lost when 
thalidomide was also given as part of induction therapy before ASCT.(85)(86) There are two 
studies of Thalidomide maintenance post conventional chemotherapy demonstrating better PFS 
compared to Interferon or interferon + Dexamethasone. (12)(13) However the OS benefit was 
there in only one of the studies.(13) The major limitation that precludes a widespread use of 
 24
thalidomide maintenance is the toxicity related to long-term administration of this agent, 
primarily peripheral neuropathy (PN). In several studies, thalidomide-induced PN led to 
discontinuation rates in the 60% range. (85)  
 
Concluding remarks 
The treatment of Multiple myeloma has evolved over time. With the availability of autologous 
stem cell transplantation and the advent of novel agents, the rate of complete response has 
increased and the progression free survival and overall survival have improved. There is a role 












Aims and Objectives 
 
 To analyze the response rate, progression free survival and overall survival of newly 
diagnosed multiple myeloma cases treated with Thalidomide-Dexamethasone as 
induction therapy. 
 To analyze impact of ASCT and Thalidomide maintenance in prolonging the progression 

















Patients and methods 
This study protocol was approved by our Institutional Review Board (IRB). 
Duration of the study: March 2004 to December 2011.  
Settings of the study: Department of Clinical Haematology.  
Diagnostic criteria: According to the International Myeloma Working Group (IMWG) 
criteria for diagnosis of Multiple myeloma, 2003. (Table-2) 
PATIENTS 
Inclusion criteria:  
 All patients with newly diagnosed multiple myeloma seen in the Department of 
Hematology between March 2004 to September 2011, who were initiated on 
Thalidomide-Dexamethasone as first line therapy. 
Exclusion criteria:  
 Patients with multiple myeloma treated with regimens other than Thalidomide-
Dexamethasone as first line therapy. 
 Patients diagnosed and initiated on Thalidomide-Dexamethasone in other 







Data collection  
After approval by the IRB, the patient data base at our institution were reviewed to identify all 
patients with newly diagnosed multiple myeloma who were initiated on Thalidomide-
Dexamethasone as first line therapy at our institute from March 2004 to September 2011.  
Medical information regarding the clinical/laboratory details at diagnosis, post treatment 
response and adverse events were obtained from the hospital records (laboratory reports/ 
physician documentation in hospital charts/hospital discharge summaries). Patients who after 
initiating therapy with TD did not have at least one response assessment were categorised as 
‘lost to follow up’ and were excluded from the analysis for progression free and overall survival. 
 
Treatment 
All patients were initiated on Thalidomide at a dose of 50mg to 100mg OD and the dose was  
increased gradually to 400mg once daily if tolerated. Dexamethasone 20mg - 40mg OD was 
given on D1-4, 9-12 and 17-21 during the first month, then on D1-4 from subsequent cycles. 
ASCT was done in patients affording transplant after they achieve a response to therapy. 
Maintenance thalidomide was initiated as per physician discretion in patients who achieve a 







The response will be assessed as per the International Myeloma Working Group uniform 
response criteria.(89) (Tables – 6 and 7)  
 
CRu (Complete response unconfirmed) 
Bone marrow is not done as a routine at the time of response assessment at our institution, except 
prior to ASCT. Hence we defined this category of response “CRu” as absence of M protein, 
















Statistical analyses were performed with SPSS (windows 11.01 version, SPSS inc, Chicago), for 
all variables. Descriptive statistics was calculated for all variables. The χ2 test/ Fishers exact test 
or t-test / Mann Whitney U test was used as appropriate to compare the differences between 
groups for response to therapy.  
Patients who were having PD, but alive at the time of last follow up and not followed up for 
more than six months or were sent on palliative intent as per discharge summary/OP chart were 
considered dead for the statistical analysis  
Overall survival (OS) was defined as time from diagnosis to death due to any cause. Progression 
free survival (PFS) was defined as time from initiation of TD to disease progression or death 
resulting from any cause. The OS and EFS was estimated using Kaplan-Meier method. For all 










A total of 242 patients with newly diagnosed MM were initiated on Thalidomide-
Dexamethasone therapy during the study period.  Of the 242 cases, 17 cases did not have even a 
single response assessment after the initiation of therapy with Thalidomide-Dexamethasone. 
These patients were only included for the analysis of baseline characteristics and excluded from 
analysis of   progression free and overall survival. Hence a total of 225 patients were available 
for response and survival analysis. 
Certain data are available on all patients, while other data are available only on a portion 
of the patients. For each result category, the numbers of patients involved are mentioned. 
Demographic data (table-8) 
The median age of the 242 patients was 54 years (range 21-80). The proportion of cases younger 
than 65 years and 50 years was 90.4% and 34.7% respectively. Males were predominantly 
represented in the 242 patients. 172(71.1%) were males and 70(28.9%) were females. The male 
female ratio was 2.45:1 
Clinical presentation (Table-9)  
Anaemia and back pain was the most common presenting feature in 59.1% and 57.4% 
respectively. Renal failure was documented in 21.1%. Vertebral wedge compression fractures 
were present in 47.9%. Pathological fractures involving the long bones were the presenting 
feature in 13 cases, with the humerus and femur being the most commonly affected bones. 
Paraparesis due to extradural cord compression was seen at the time of diagnosis in 17 cases 
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(7%). Unexplained weight loss and pyrexia of unknown origin were present at diagnosis in 6.6% 
and 4.9% of cases respectively. Seven patients presented with infection, urinary tract infection in 
5, pneumonia and diarrhea in one patient each. Peripheral neuropathy, DVT, lymphadenopathy, 
proptosis and polyarthritis were some of the rarer presentations.  Hypertension (11.9%) and 
diabetes mellitus (9%) was the most common comorbidities seen at diagnosis. Other 
comorbidities included hypothyroidism (3 patients), bronchial asthma, coronary artery disease 
and benign prostatic hypertrophy in 2 patients each, ankylosing spondylitis, previous renal cell 
carcinoma, previous cerebrovascular accident and Parkinson disease in one patient each. 
Anaemia, Thrombocytopenia and Leukopenia (Table-10) 
Anaemia, thrombocytopenia and leukopenia were present in 59.1% of patients, 6.6% and 3.3% 
respectively. Serum creatinine >2mg / dl and a corrected serum calcium >10.5 mg/dl was 
documented in 21.1% and 19.8% respectively.  
Hypoalbuminemia and β2 microglobulin <3.5 mg/l was present in 46.7% and 35.7% 
respectively. Elevated uric acid and serum LDH was documented in 55.8% and 20.9% of 
patients. Urine BJP was positive in 63.6% of patients and the 24 hour urine protein greater than 
200mg / day was documented in 75.4%. 
Heavy chain myeloma was predominant type with IgG, IgA and IgM constituting 55.7%, 13.2% 
and 1.6% respectively. The type of heavy chain was not available in 16 cases. Light chain 
myeloma and non-secretory disease constituted 18.2% and 1.2% respectively. Biclonal M band 
was present in 8 cases (3.3%). Associated amyloidosis was present in 4 patients.    
Bone involvement was present in a total of 200 patients (82.6%). Lytic lesion were seen in 134 
(55.3%) of cases. Long bone pathological fractures were seen in 5.3%. Plasmacytoma was 
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present in 57% of cases, out of which extramedullary plasmacytoma was present in 6 cases. 
Sclerotic lesions were present in 2 cases. Osteopenia was present in 11.9% of cases.(Table-11) 
Progression of MGUS and solitary plasmacytoma to symptomatic multiple myeloma occurred in 
1 and 5 patients respectively. The time to progress to MM from the diagnosis of MGUS was 52 
months and from the diagnosis of solitary plasmacytoma was between 44-65 months with a mean 
of 52 months. (Table-12) 
The proportion of patients according to the ISS stage  was 25.4%, 32.5% and 42.1% for ISS I, II 
and III respectively.  The proportion of patients according to the DSS was 12.8%, 35.5% and 
51.7% respectively for DSS I, II and III respectively. (Table-13)  
 Treatment with Thalidomide-Dexamethasone (TD) (Table-14, 15 & 16) 
All the 242 patients were initiated on TD. Seventeen cases were lost to follow up. Among the 
remaining 225 patients, the median number of cycles administered was 7 (range: 1 to 27). TD 
was administered for >1yr in 40 cases. The median dose of Thalidomide was 200mg OD (range: 
50 – 400mg OD). The median dexamethasone dose was 40mg OD (range: 8 -40 mg OD). DVT 
prophylaxis was given to 219 cases, 217 receiving aspirin. One patient continued clopidogrel, 
which was started for cerebrovascular event in the past. One patient with a lower limb DVT at 
presentation was on anticoagulation with Sintrom prior to starting TD. No prophylaxis was given 
in 23 patients. Bisphosphonates were given to 173 patients (71.5%).    
Response to TD (Table-17) 
Of the 225 patients available for analysis, 181(80.5%) achieved a response and 44 were non 
responders. CR, CRu, VGPR and PR   rates were 4.5%, 4.5%, 31.1%, and 40.4% respectively. 
The median time to response was 3 months (range: 1month to 13 months). 
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The response according to ISS and DSS (Table-18) 
Response and survival did not vary according to ISS and DSS categories. The overall survival of 
the ISS I, II and III were 90.1%, 79.6%, and 72.7% at a median follow up of 22.5 months, 26 
months and 28 months respectively (p=0.055). The overall survival of the DSS I, II and III were 
86.6%, 79.5%, and 78.5% at a median follow up of 20 months, 25 months and 25.5 months 
respectively.    
After achieving an initial response to TD 153 developed progressive disease. The median time to 
progression was 11 months (range 1-86 months). 
Subsequent course 
Among the responders, 13 patients (ASCT group) underwent upfront ASCT post induction 
therapy, 49 patients (Maintenance group) received Thalidomide maintenance (one patient 
received Lenalidomide maintenance) therapy, while 119 patients (No treatment group) did not 
receive any further therapy. 
Maintenance group (Figure-4) 
Maintenance was initiated in 49 of 181 patients achieving a response to TD. Thalidomide at a 
median dose of 100mg OD (range: 50mg to 200mg OD) was given to 48 patients. One patient 
received Lenalidomide maintenance. Duration of maintenance therapy ranged from 2-69 months 
with a median duration of 14 months. The median dose of Thalidomide during maintenance was 
100mg OD.   
Of the 49 patients who were on maintenance therapy 21 remain in remission at a median follow 
up of 32 months and 28 had progressive disease with a median time to progression of 17.5 
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months. All 28 patients with progressive disease received treatment with various second line 
regimens and one patient underwent ASCT (follow up of 15 months), while 7 patients expired 
(median follow up of 37 months) with progressive disease and 20 patients were alive (median 
follow up of 50 months). 
No treatment group (Figure-5)  
Of the 119 patients who neither received maintenance nor ASCT, 40 remained in continuous 
response (median follow up of 8 months), while 79 had progressive disease. The median time to 
progression was 11 months. Among the 79 patients who relapsed, 4 did not receive any further 
therapy and the rest were treated with various second line therapies. Nine of these patients 
underwent a successful ASCT out of which 7 are alive, in continued response (median follow up 
of 35 months) and 2 are dead with progressive disease.   Among the 79 patients who relapsed, 17 
had refractory disease and expired due to progressive disease (median follow up of 17 months) 
and 49 are alive after subsequent therapy. 
Non – responders (Figure-6) 
Of the 44 patients who were non responders (Minimal response-14, No response-23, Progressive 
disease-7), 5 patients did not undergo any further therapy while 39 were treated with salvage 
therapy. Six patients underwent ASCT after achieving a response and 5 patients of this group are 
alive (median follow up of 37 months). Thirteen expired due to progressive disease (median 
follow up of 12 months) and 20 patients were alive at last follow up after salvage therapy 




A total of 29 patients underwent ASCT, 13 patients post TD induction and 16 patients post 
salvage therapy. The median age of the patients undergoing ASCT was 50 yrs (range: 29 to 59 
yrs). The median from diagnosis to ASCT was 12 months (range: 4 -32 months). The number of 
chemotherapy regimes received prior to the transplant was one in 13 patients, 2 in 11 patients 
and three in 5 patients. Pre transplant CR/CRu was present in 9 patients, VGPR in 11 patients 
and PR in 9 patients. The median dose of Melphalan was 200mg/m2. The median CD34 cell dose 
was 3.8 X106 cells/ Kg (range: 1.15 to 17 X106 cells/ Kg). Mucositis was occurred in all patients 
with grade III/IV in 23 patients. The median time to ANC >500/cu.mm, >1000/cu.mm and 
platelet >20000/cu.mm was 11 days, 12 days and 12 days respectively. The median duration of 
post ASCT follow up was 15 months (range: 1-74 months). Post transplant CR/CRu was 
achieved in 15 patients, VGPR in 8 patients, PR in 5 patients and one patient had progressive 
disease. Eleven patients had progressive disease post transplant and the median time to progress 
post transplant was 13 months (range: 2-44 months).     
Among the 13 patients who underwent upfront ASCT, all but one achieved ≥VGPR and one 
patients achieved PR. Except for the 2 patients who relapsed post ASCT, the 11 of the 13 
patients receiving upfront ASCT were alive in continuous remission, with a median follow up of 
72 months. (Figure-3) 
An additional 16 patients underwent ASCT after achieving remission with salvage therapy and 
11 achieved ≥ VGPR and 4 PR while one patient had PD. Among these 9 had progression of 
disease post transplant with median time to progression of 13 months (range: 4-44 months) and 
received further chemotherapy. Among the 16 patients, 13 are alive and 3 patients are dead with 
progressive disease at a median follow up of 33 months.  
 36
Post ASCT maintenance was initiated in 14 patients, 11 received Thalidomide and 3 received 
Lenalidomide. The median dose of thalidomide maintenance was 100mg OD (range: 100 – 
200mg OD). The median duration of maintenance therapy was 10 months (range: 2-30 months). 
Seven patients who had maintenance post ASCT had PD, with a median TTP of 13 months 
(range: 6-44 months). Four patients without maintenance post ASCT had PD, with a median TTP 
of 12.5 months (range: 4-16 months).  
Adverse effect (Table-22 and 24) 
Peripheral neuropathy due to thalidomide was noted in 21.3% of patients. They were mainly 
sensory symptoms with no documented motor deficits. However nerve conduction studies were 
not done to document neuropathy. Thalidomide had to be stopped due to neuropathy in 8 patients 
at the following time periods: 3mo(2 patients), 9mo(1 patient), 15mo(1 patient), 18mo(2 
patients), 19 mo (1 patient) and 32 mo(1 patient). In an additional 11 patients, the dose of 
thalidomide had to be reduced. Constipation was the most commonly encountered adverse effect, 
occurring in about 22.2%. However it usually occurred during the initiation of therapy and 
responded to laxatives and settled over time on continuation of thalidomide. Hyperglycemia was 
seen in about 12.1% related to Dexamethasone. Somnolence and rash were noted in 5 patients 
each. The rash subsided on discontinuation of Thalidomide. However 3 of the patients continued 
thalidomide uneventfully. DVT of the lower limb was present in one patient at the time of 
diagnosis, who was initiated on TD after adequate anticoagulation with Sintrom. He did not 
develop any recurrent thrombo-embolic manifestations. Six patients (2.6%) developed 
documented venous thrombosis while on Thalidomide. Except for one of these patients all were 
on aspirin prophylaxis. One patient had associated polycythemia vera with JAK 2 mutation. One 
patient had chronic pulmonary thromboembolism and one had cortical vein thrombosis. Other 
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rare adverse events noted were grade IV myopathy, depression, cushing syndrome, syncope, 
seizures, pancreatitis and neutropenia in one patient each.    
Overall survival (OS) and Progression free survival (PFS) 
Two hundred and twenty five patients could be analyzed for PFS and OS. The median 
follow up was 24 months (range: 1-96 months). There were a total of 45 deaths, all due to 
progressive disease and none were related to toxicity of therapy. Among the 45 deaths 13 were 
documented in our institution. The remaining cases were considered dead as per criteria defined 
in the methods. 
The median PFS (Figure-7) was 14 months (95% CI: 21.3 to 29.6 months) with the PFS at 24 
months and 36 months were 38.3% and 26.3% respectively. The median for OS (Figure-8) has 
not been reached and the mean OS was 70 months (95% CI: 64 to 77 months). The OS at 24 
months and 36 months were 84.5% and 76.9% respectively. 
Median PFS for patients undergoing upfront ASCT (Figure-9) has not been reached and the 
mean PFS is 69.1 months (95% CI: 47.8 to 90.3 months). The PFS at 24 and 36 months were 
100% and 83.3% respectively. Median OS (Figure-10) of patients undergoing upfront ASCT 
group has not been reached and the mean OS was 70 months (95% CI: 56 to 83 months). The OS 
at 24 and 36 months were 95.4% and 82.7% respectively.  
In patients receiving maintenance after TD, the median PFS (Figure-9) was 38 months (95% CI-
23.4 to 52.5 months) with the PFS at 24 months and 36 months were 66.6% and 55.1% 
respectively. The median OS (Figure-10) in the maintenance group has not reached and the mean 
OS was 81 months (95% CI-71 to 91 months) and the OS at 24 months and 36 months were 
95.6% and 92.4% respectively.  
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In patients who did not receive either ASCT or maintenance post TD, the median PFS (Figure-9) 
was 14 months (95% CI: 17 to 23.6 months) with the 24 month and 36 month PFS being 31% 
and 14.7% respectively. The median OS (Figure-10) has not been reached in the no ASCT/ no 
maintenance group with mean OS of 61 months (95% CI: 52 to 70 months). The OS at 24 and 36 
months in this group was 82.9% and 75.2% respectively.  
The ASCT group had a statistically significant PFS benefit over the Maintenance group, which 
had a statistically significant better PFS than the No ASCT / No maintenance group (p=0.000). 




  The median age of the 242 patients was 54 years (range 21-80). The proportion of patients 
younger than 65 years was 90.4% and this is far higher than what is reported in the western 
population. The proportion of cases younger than 65 years was 90.4%. The median age at 
diagnosis reported in western literature is between 60yrs to 70 yrs.(19),(22) The median age of 
the two phase III trials of TD upfront treatment were 64 and 65 years, much older than in this 
study.(11)(84)   
Males were predominantly represented in the 242 patients. 172(71.1%) were males and 
70(28.9%) were females. The male female ratio was 2.45:1. In the published western literature  
males are predominant with 55%.(2) Anaemia, thrombocytopenia and leukopenia were present in 
59.1% of patients, 6.6% and 3.3% respectively. A review of 1027 patients from Mayo clinic 
reported anaemia in 72% of patients at diagnosis.(41)(42). Serum creatinine >2mg / dl and a 
corrected serum calcium >10.5 mg/dl was documented in 21.1% and 19.8%, which is similar to 
that reported from the Mayo clinic. (41) Similar to the present study the  bone involvement were 
reported in 80% of the cases, which includes lytic lesions, pathological fractures and 
osteopenia.(41) However the pathological fractures were less in the present study compared to 
that in the literature of 13%(41). The type of myeloma (Heavy chain, light chain and non 
secretory) was similar in the present study compared to the mayo clinic study. (41)  
The proportion of patients according to the DSS staging are similar to a report published in  
2007.(90)   
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Progression of MGUS and solitary plasmacytoma to symptomatic multiple myeloma occurred in 
1 and 5 patients respectively. MGUS and solitary Plasmacytomas are known to progress to overt 
MM.(15),(16) A recent publication showed that all cases of overt MM were preceded by 
MGUS.(3) 
The reported adverse effects of TD therapy in the literature are constipation 33% to 72%, 
peripheral neuropathy 3.4% to 72%, rash 0% to 61%, thrombosis 4% to 18.8% and infection in 
7.3%, which are similar to that in the present study. (81) (82) (79) (80) (71) (83) (84) (91) The 
incidence of thrombotic complications in this study is lower (2.6%) compared to that reported in 
the western countries. This may be related to the use of aspirin prophylaxis in majority of 
patients (89.6%) in the current study. Palumbo et.al, has reported a reduction in the incidence of 
thrombosis in patients treated with Melphalan, Thalidomide and Dexamethasone (MPT) with 
enoxaparin prophylaxis to 3%.(92) 
In the largest phase III randomized trial of TD treatment in newly diagnosed MM, the median 
number of cycles was 6.9 and median dose was 200mg OD, which is similar to the present study. 
(72)  
Of the 225 patients available for analysis, 181(80.4%) achieved a response while 44 were non 
responders. CR, Cru, VGPR and PR were achieved in 4.5%, 4.5%, 31.1%, and 40.4% 
respectively. The time to response ranged from 1 month to 13 months with a median time to 
response of 3 months. The various phase II and Phase III trials showed an overall response of 
63% to 76%, VGPR or greater response according to published literature ranged between 19% to 
43.8% and CR was reported in 2% to 10%, which is similar to the present study. (Table 24)   
 41
The median time to progression was 11 months (range 1-86 months). The median time to 
progress in a phase III randomized trial of TD treatment in newly diagnosed MM without ASCT 
was 22.6 months. (72)    
Age, sex, anaemia, renal failure, hypercalcemia, bone involvement, presence of plasmacytoma, 
hypoalbuminemia and β2 microglobulin >3.5 mg/l, type of myeloma, i.e., heavy chain, light 
chain, biclonal or nonsecretory myeloma, bone marrow plasma cell percentage below or above 
50%, ISS and DSS staging, urine BJP and 24 hour urine protein did not significantly affect the 
response, PFS and OS to Thalidomide -Dexamethasone therapy. Age is an important prognostic 
marker with younger age group having a better response and overall survival compared to older 
age group. In this study 34.7% of patients were younger than 50 years. Survival advantage in age 
<50yrs compared to age >50 yrs, both after conventional therapy and after ASCT has been 
reported based on study of 10549 patients (median, 5.2 years vs. 3.7 years; P < .001). (49) 
However in the present study age was not significant for both OS and PFS.  
In the group of patients who received maintenance therapy, the median PFS was 38 months (95% 
CI-23.4 to 52.5 months) and the PFS at 24 months and 36 months were 66.6% and 55.1% 
respectively. The median OS has not been reached and the mean OS was 81 months (95% CI-71 
to 91 months) and the OS at 24 months and 36 months were 95.6% and 92.4% respectively. 
These findings were statistically significant compared to patients who did not receive 
maintenance therapy, where the median PFS was 14 months (95% CI: 17 to 23.6 months) and the 
24 month and 36 month PFS was 31% and 14.7% respectively. The median OS however has not 
been reached with a mean OS of 61 months (95% CI: 52 to 70 months). The OS at 24 and 36 
months in this group was 82.9% and 75.2% respectively. Offidani et.al., published data on 
Thalidomide + Dexamethasone maintenance post induction therapy (median age of 72 yrs) and 
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showed a PFS at 24 months of 63% and OS at 24 months of 83 %.(12) In another study 
Thalidomide + Interferon maintenance therapy in elderly subjects after induction therapy with 
either TD or MP by Ludwig, H. et al, the median PFS was 27.7 months and the median OS was 
52.6 months.(13) The superior PFS and OS in the present study compared to the published data 
could be probably due to the younger age of the cases. 
The number of chemotherapy regimens received prior to the transplant, pre transplant status, the 
CD34 cell dose, baseline characteristics at diagnosis and post transplant maintenance therapy did 
not significantly impact OS or time to progress after autologous transplant. The median duration 
of post ASCT follow up was 15 months (range: 1-74 months). Post transplant CR/CRu + VGPR 
has been achieved in 23(79.3%) of the total 29 patients. Data in literature shows a post TD 
induction and ASCT a >VGPR rate of 44%(11)  and 54%. (86)  
Post ASCT maintenance was initiated in 11 patients, 11 received Thalidomide and 3 received 
Lenalidomide. Seven patients of the post ASCT maintenance group had PD, with a median TTP 
of 13 months (range: 6-44 months). Four patients of the no maintenance post ASCT group had 
PD, with a median TTP of 12.5 months (range: 4-16 months). Published literature on 
Thalidomide maintenance post ASCT show PFS and OS advantage in 2 trials(87)(88) and PFS 
advantage but no OS advantage in one trial.(86) 
The response to TD (CR + CRu vs. VGPR vs. PR) was significantly associated with a better PFS 
(p=0.000), however was not significant for OS (p=0.232). In the IFM 90 trial the impact of 
achieving CR or at least very good partial remission (VGPR) on the OS was shown. Patients who 
achieved a CR or VGPR had a longer OS than patients who achieved only partial remission 
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(PR). The influence of the depth of response pre and post HDT/ASCT on both EFS and OS was 
also demonstrated in a study by Lahuretta JJ et.al.(68)  
The median follow up duration was 24 months (range: 1-96 months). The median PFS was 14 
months (95% CI: 21.3 to 29.6 months). The PFS at 24 months and 36 months were 38.3% and 
26.3%. The median PFS of the TD arm in a randomized study by Rajkumar et.al., was 14.9 
months which is similar to that of the present study.(84)  
The median for OS has not been reached and the mean OS was 70 months (95% CI: 64 to 77 
months). The OS at 24 months and 36 months were 84.5% and 76.9%. The median OS of 
patients undergoing ASCT after TAD reported in literature is 73 months. (86) The two Phase III 










 A total of 242 newly diagnosed patients were initiated on TD, out of which 225 were 
available for analysis. The median follow up was 24 months (range: 1-96 months) 
 The median age of the cohort was 54 years which is younger than that reported in the 
literature. 
 A total of 80.5% of patients responded to TD, with a ≥VGPR rate of 40.1% and a CR + 
CRu rate of 9%. 
 ISS and DSS did not have a significant effect on the response or survival. 
 PFS in the three groups ASCT, Maintenance, No treatment (No ASCT/ No maintenance 
were) was 83.3%, 55.1%, and 14.7% at 36 months respectively. (p=0.0000). 
 PFS and OS of the entire cohort of patients were 26.3% and 76.9% at 36 months 
respectively.  
 Incidence of neuropathy was 21.3% and thrombosis was 2.6%. Thalidomide had to be 
discontinued in 8 patients due to peripheral neuropathy and in 3 patients due to rash. 
Dose reduction of thalidomide was done in 11 patients due to peripheral neuropathy.  
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 Limitations of the study: 
1. It is a retrospective study. 
2. No randomization of cases to ASCT, maintenance or no ASCT/no maintenance therapy. 
















• Thalidomide – Dexamethasone is an effective first line therapy for multiple 
myeloma. 
• Autologous stem cell transplantation and Thalidomide maintenance therapy 
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Fig.1: Timeline depicting the history and treatment of Myeloma 
 
 
Fig.2: Sarah Newbury, the first reported patient with multiple myeloma. (A) Bone destruction in the sternum. (B) The 








Figure-3: Flow chart depicting the response to Thalidomide – Dexamethasone and 
subsequent course of patients undergoing upfront ASCT. R-Responder, NR-Non responder, LTFU-
Lost to follow up, ASCT – Upfront Autologous stem cell transplantation group, Maint – Thalidomide maintenance 
group, No treatment group – No Autologous stem cell transplantation and no maintenance group, PD-Progressive 
disease, mo-months, med f/u- Median follow up, CTD- Cyclophosphamide + Thalidomide + Dexamethasone, LD – 
Lenalidomide + Dexamethasone, PAD – Bortezomib + Adriamycin + Dexamethasone. CR-Complete remission, 













Flow chart depicting the response to Thalidomide – Dexamethasone and subsequent course 
of patients initiated on thalidomide maintenance. R-Responder, NR-Non responder, LTFU-Lost to 
follow up, ASCT – Upfront Autologous stem cell transplantation group, Maint – Thalidomide maintenance group, 
No Treatment group – No Autologous stem cell transplantation and no maintenance group, mo-months, med f/u- 
Median follow up, PD-Progressive disease,  Cyclo-Pred-Cyclophosphamide + Prednisolone, CTD- 
Cyclophosphamide + Thalidomide + Dexamethasone, MP-Melphalan + Prednisolone, MPT – Melphalan + 
Prednisolone + Thalidomide, LD – Lenalidomide + Dexamethasone, , PAD – Bortezomib + Adriamycin + 
Dexamethasone. CR-Complete remission, CRu-Complete response unconfirmed, VGPR-Very good partial response, 









Figure-5: Flow chart depicting the response to Thalidomide – Dexamethasone and 
subsequent course of patients not initiated on thalidomide maintenance or ASCT after 
initial response to TD. R-Responder, NR-Non responder, LTFU-Lost to follow up, ASCT – Upfront 
Autologous stem cell transplantation group, Maint – Thalidomide maintenance group, No treatment group – No 
Autologous stem cell transplantation and no maintenance group, PD-Progressive disease, mo-months, med f/u- 
Median follow up, PD-Progressive disease, Cyclo-Dex- Cyclophosphamide + Dexamethasone, Cyclo-Pred-
Cyclophosphamide + Prednisolone, CTD- Cyclophosphamide + Thalidomide + Dexamethasone, MP-Melphalan + 
Prednisolone, MPT – Melphalan + Prednisolone + Thalidomide, LD – Lenalidomide + Dexamethasone, LLD – 
Lenalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone, PAD – Bortezomib + Adriamycin + 
Dexamethasone,ST-Salvage therapy, Tt-Treatment, CR-Complete remission, CRu-Complete response unconfirmed, 







6: Flow chart depicting the response to Thalidomide – Dexamethasone and subsequent 
course of NR. R-Responder, NR-Non responder, LTFU-Lost to follow up, PD-Progressive disease, mo-months, 
med f/u- Median follow up, PD-Progressive disease, Cyclo-Dex- Cyclophosphamide + Dexamethasone, Cyclo-Pred-
Cyclophosphamide + Prednisolone, CTD- Cyclophosphamide + Thalidomide + Dexamethasone, MP-Melphalan + 
Prednisolone, MPT – Melphalan + Prednisolone + Thalidomide, LD – Lenalidomide + Dexamethasone, LLD – 
Lenalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone, PAD – Bortezomib + Adriamycin + 
Dexamethasone,ST-Salvage therapy, Tt-Treatment, CR-Complete remission, CRu-Complete response unconfirmed, 
VGPR-Very good partial response, PR-Partial response. 
*Salvage Therapy of 13 expired patients - 1 len/1 Bort, 5CTD,     4 CD,   2 MPT  







Progression free survival 
 
Figure-7. Kaplan Meier curve of Progression free survival (PFS) of the entire cohort of 225 
patients available for analysis. Events (Progressive disease/Relapse) -153, Mean PFS -25.5 
months and Median PFS -14 months (95%CI-10.7 to 17.2). The PFS at 24 and 36 months are 









 Overall survival 
 
Figure-8. Kaplan Meier curve for overall survival(PFS) of the entire cohort of 225 patients 
available for analysis. Events (Death) -45, Median - not reached,    Mean OS -70 months 
(95%CI- 64  to 77). The OS at 24 and 36 months are 84.5 months and 76.9 months respectively. 









 Progression free survival 
 
Figure-9.  Kaplan Meier curve for progression free survival (PFS) of the three groups: 
ASCT- 13 pts. (Green), Maintenance – 49 pts. (Pink) and No ASCT/No Maintenance - 119 
pts. (Yellow). Events (Progressive disease).Median - not reached in the ASCT group and the 
mean PFS was 69.1 months (95% CI – 47.8 to 90.3). The median PFS for the Maintenance group 
was 38 months (95%CI-23.4 to 52.5). The median PFS for the No ASCT/ No Maintenance group 
was 14 months (95%CI-9.9 to 18.06). The PFS at 24 and 36 months were 100% & 83.3%, 66.6% 












Figure 10.  Kaplan Meier curve for overall survival (OS) of the three groups: ASCT- 29 
pts. (Green), Maintenance – 48 pts. (Pink) and No ASCT / No Maintenance - 110 pts. 
(Yellow). Events (Death) (ASCT- 5, Maintenance – 7 and No ASCT / No Maintenance – 18.) 
Median - not reached in all the three groups. The OS at 24 and 36 months in the three groups 
were 95.45% & 82.73%, 95.6% & 92.4% and 82.96% & 75.23% in the ASCT, Maintenance and 














Bone pain (especially back pain) 58 
Fatigue (typically caused by anemia) 32 
Pathologic fracture 26 to 34 
Weight loss 24 
Paresthesias 5 
Fever 0.7 
None (asymptomatic) 34 
Anaemia 73 
Renal failure 19 
Hypercalcemia 13 
 
Table-2. IMWG criteria for diagnosis of Myeloma.  
MGUS  Asymptomatic  
myeloma  
Symptomatic myeloma  
M-protein in serum <30 g/l  M-protein in serum >30 g/l  
and/or  
Bone  marrow  clonal  plasma 
cells >10 %  
M-protein in serum and/or 
urine**  
 
No related organ or tissue 
impairment ((no end organ 
damage including bone 
lesions)  
 
 Bone marrow (clonal) 
plasma cells or biopsy 
proven plasmacytoma  
 
No related organ or tissue 
impairment ((no end organ 
damage including bone 
lesions)  
 
No related organ or tissue 
impairment (no end organ 
damage including bone 
lesions) or symptoms  
 
Myeloma-related organ or 
tissue impairment (including 
bone lesions)  
 
MGUS-Monoclonal gamopathy of undetermined significance                                                                       *If flow 
cytometry is performed, most plasma cells (> 90%) will show a neoplastic phenotype.              Some patients may 
have no symptoms but have related organ or tissue impairment.                                  The European Myeloma 
Network has provided a practical guidance on the optimal methods for flow cytometry(49).                                                                      
** No specific concentration required for diagnosis. A small percentage of patients have no detectable M-protein in 
serum or urine but do have myeloma-related organ impairment (ROTI) and increased bone marrow plasma cells 








Table-3 - Myeloma-related organ or tissue impairment (ROTI)(4) 
Clinical effects due to myeloma  Definition  
*Increased calcium levels  Corrected serum calcium >0.25mmol/l above 
the upper limit of normal or >2.75mmol/l  
*Renal insufficiency  Creatinine>173mmol/l (2mg/dl) 
*Anaemia  Haemoglobin 2 g/dl below the lower limit of 
normal or haemoglobin <10 g/dl  
*Bone lesions  Lytic lesions or osteoporosis with 
compression fractures  
(MRI or CT may clarify)  
Other   Symptomatic hyperviscosity,       
amyloidosis, recurrent bacterial infections   
(> 2 episodes in 12 months)  
  














Table-4. Phase II and Phase III trials of Thalidomide combination therapy in                 
newly diagnosed MM. 
Regimen 





PFS OS Ref. 
 CR+PR%CR/≥VGPR CR+PR CR/≥VGP    
TD (50) 
Phase II 

















TD (71)  
PhII 
66 8/17 NR NR NR NR (84)  















































































































ASCT-Autologous stem cell transplantation, PFS-Progression free survival, OS-Overall survival, CR-Complete response, PR-
Partial response, VGPR-Very good partial response, TD-Thalidomide+Dexamethasone, VAD-
Vincristine+Adriamycin+Dexamethasone, DASCT-Double Autologous stem cell transplantation, NR-Not reported, TTP-Time to 











           Table 5. Thalidomide Maintenance Trials  
Trial/year  Study design PFS/EFS OS Ref 
Offidani et.al. 
2009  
Thal + Dex vs. 
IFN + Dex 
2 yr 
63% vs. 32% 
(p=0.024) 
2 yr 
84% vs. 68% 
(p=0.03) 
(12) 
Ludwig, H. et 
al. 
 2010  
       Thal+IFN vs. 
             INF 






Attal, et al. 
2006. 
  
      A-no therapy vs.  
    B-pamidronate    
vs.  
              C- P+T 
3 yr EFS 
52 % vs. 36% 
(p<0.009) 
4 yr 
87% vs. 75% 
(p<0.04) 
(90)  
Spencer, et al.  
2009  
 
       AP vs. AP+T  
3 yr PFS 
42 % vs. 23% 
(p<0.001) 
3 yr 









INF vs. T for 
maintenance 
Median EFS 
34m vs. 22m 
(p<0.001) 
median 
73m vs. 60m 
(p=0.77) 
(86) 
PFS-Progression free survival, OS-Overall survival, EFS-Event free survival, Thal + Dex-Thalidomide+Dexamethasone, IFN + 
Dex-Interferon+Dexamethasone, Thal+IFN-Thalidomide+Interferon, IFN-Interferon, P+T-Pamidronate+Thalidomide,VAD-
















Table - 6. International Myeloma Working Group uniform response criteria: CR and other 
response categories (89) 
Response subcategory Response criteriaa 
Scr CR as defined below plus Normal FLC ratio and 
Absence of clonal cells in bone marrowb by immunohistochemistry or 
immunofluorescencec 
CR Negative immunofixation on the serum and urine and Disappearance of 
any soft tissue plasmacytomas and <5% plasma cells in bone marrowb 
VGPR Serum and urine M-protein detectable by immunofixation but not on 
electrophoresis or 
90% or greater reduction in serum M-protein plus urine M-protein level 
o100mg per 24 h 
PR ≥50% reduction of serum M-protein and reduction in 24-h urinary M-
protein by ≥90% or to <200mg per 24 h  
If the serum and urine M-protein are unmeasurable, a ≥50% decrease in 
the difference 
between involved and uninvolved FLC levels is required in place of the M-
protein criteria 
If serum and urine M-protein are unmeasurable, and serum free light assay 
is also unmeasurable, ≥50% reduction in plasma cells is required in place 
of M-protein, provided baseline bone marrow plasma cell percentage was 
≥30% 
In addition to the above listed criteria, if present at baseline, a ≥50% 
reduction in the size 
of soft tissue plasmacytomas is also required 
SD (not recommended for use as an 
indicator of 
response; stability of disease is best 
described by 
providing the time to progression 
estimates) 
Not meeting criteria for CR, VGPR, PR or progressive disease 
Abbreviations: CR, complete response; FLC, free light chain; PR, partial response; SD, stable disease; sCR, 
stringent complete response; VGPR, very good partial response. 
a All response categories require two consecutive assessments made at anytime before the institution of any new 
therapy; all categories also require no known evidence of progressive or new bone lesions if radiographic studies 
were performed. Radiographic studies are not required to satisfy these response requirements. 
b Confirmation with repeat bone marrow biopsy not needed. 
c Presence/absence of clonal cells is based upon the k/l ratio. An abnormal k/l ratio by immunohistochemistry and/or 
immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of 














Table-7. International Myeloma Working Group uniform response criteria: disease 
progression and relapse (89) 
Relapse subcategory Relapse criteria 
Progressive disease  
To be used for calculation of time to progression and 
progression-free survival end points for all patients 
including those in CR (includes primary progressive 
disease and disease progression on or off therapy) 
Progressive Disease: requires any one or more of the 
following: 
 Increase of ≥25% from baseline in Serum M-component 
(the absolute increase must be X0.5 g/dl) and/or 
Urine M-component (the absolute increase must be 
≥200mg/24 h) and/or 
Only in patients without measurable serum and urine M-
protein levels: the difference between involved and 
uninvolved FLC levels. The absolute increase must be 
>10mg/dl. 
Bone marrow plasma cell percentage: the absolute % must 
be >10% 
Definite development of new bone lesions or soft tissue 
plasmacytomas or definite increase in the size of existing 
bone lesions or soft tissue Plasmacytomas. 
Development of hypercalcemia (corrected serum calcium 
>11.5mg/dl or 2.65mmol/l) that can be attributed solely to 
the plasma cell proliferative disorder 
Clinical relapse Clinical relapse requires one or more of: 
Direct indicators of increasing disease and/or end organ 
dysfunction (CRAB features). It is not used in calculation of 
time to progression or progression-free survival but is listed 
here as as something that can be reported optionally or for 
use in clinical practice 
1. Development of new soft tissue plasmacytomas or bone 
lesions 
2. Definite increase in the size of existing plasmacytomas or 
bone lesions. A definite 
increase is defined as a 50% (and at least 1 cm) increase as 
measured serially by the sum of the products of the cross-
diameters of the measurable lesion 
3. Hypercalcemia (411.5mg/dl) [2.65mmol/l] 
4. Decrease in hemoglobin of X2 g/dl [1.25mmol/l] (see 
Table 3 for further details) 
5. Rise in serum creatinine by 2mg/dl or more [177 mmol/l 
or more] 
Relapse from CRa 
(To be used only if the end point 
studied is DFS) 
 
Any one or more of the following: 
Reappearance of serum or urine M-protein by 
immunofixation or electrophoresis 
Development of >5% plasma cells in the bone marrow 
Appearance of any other sign of progression (i.e., new 
plasmacytoma, lytic bone lesion, or hypercalcemia see 
below) 
Abbreviations: CR, complete response; DFS, disease-free survival. 
All relapse categories require two consecutive assessments made at any time before classification as relapse or 
disease progression and/or the institution of any new therapy. 
For progressive disease, serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-
component is ≥5 g/dl. 
Relapse from CR has the 5% cutoff versus 10% for other categories of relapse. 
For purposes of calculating time to progression and progression-free survival, CR patients should also be evaluated 




Age distribution                                          No.   
 
Total  242  
Range 21 to 80 yrs 
Median 54 yrs 
Mean 53.38 yrs 
Age <65 219(90.4%)  
Age >65 23(9.6%)  
Age>50 158(65.3%) 
Age<50 84(34.7%) 
Sex distribution  
Males  172(71.1%)  
Females 70(28.9%)  



















Table-9. Presenting Features 
 
Presentation  No.  %  
Anaemia  143  59.1  
Renal failure* 51  21.1  
Weight loss  16  6.6  
Symtoms related to bone involvement 
Back pain  








       Humerus  
       Femur 
       Clavicle 
       Ulna 








Fever  12  4.9  
Symptomatic hypercalcemia  7  2.8  
Bleeding  5  2.06  
Infection 
       UTI 
       Pneumonia 






Peripheral neuropathy  2  0.8  
Polyarthritis  2  0.8  
Ureteric/renal calculi  2  0.8  
Proptosis  1  0.4  
Lymphadenopathy  1  0.4  
DVT#  1  0.4  
         *Renal failure is defined as Sr. Creatinine ≥2mg/dl. 














                    Baseline characteristics                                                   No. (%)  
Haemoglobin , Median-(n=242) 9.3 g/dl (3.3 – 16.8 g/dl) 
Hb <10g/dl (%) 143(59.1%) 









1.1mg/dl (0.6 -21.3mg/dl) 
Cr <2mg/dl 0.6 -21.3 mg/dl  




Ca <10.5mg/dl 194(80.2%) 




Alb <3.5g/dl 112(46.7%) 
Alb ≥3.5g/dl 128(53.3%) 
B2 microglobulin, median, (n=210)  4.5(0.4-38) 
<3.5 75(35.7%) 
≥3.5 <5.5 47(22.4%) 
≥5.5 88(41.9%) 
 65
 Hb-Haemoglobin, Cr-Creatinine, Ca-Calcium, Alb-Albumin 
 
 
Table-10.Baseline characteristics continued 
 
Baseline characteristics                                                No. (%)  
Sr.Uric acid, median (n=165)  6.6mg/dl(0.2-16.3) 
>7mg/dl (Elevated)  73(44.2%) 
Sr.LDH, median (n=182) 348 u/dl(0-1138) 
>460 u/dl (Elevated) 
 
38(20.9%) 
Urine BJP, (n=228)  
Positive 145(63.6%) 
24 Hour urine protein, median (n=142)  0.949g/day(0-14.9) 
≥200mg/day 107(75.4%) 

















BM % plasma cells <50% 
                               >50% 
62 (25.6) 
180(74.4) 
M band Quantification 
≤3 g/dl 
>3 to ≤5g/dl 








             LDH-Sr.Lactate dehydrogenase, Urine BJP-Urine Bence Jones Protein. 
 
Table-11.Bone involvement 
Bone involvement (n-=242)                                                                     No. (%)  
Present  200(82.6%) 
Lytic lesions  134(55.3%) 
Wedge compression fracture of vertebrae  116(47.9%) 
Pathological fractures of long bones  13(5.3%) 
Plasmacytoma  57(23.6%) 
Single Bony Plasmacytoma 41 











Multiple Plasmacytomas  10 
Osteopenia  29(11.9%) 
Sclerotic lesion  2(0.8%) 
 
Table-12.Progression from MGUS/ Solitary Plasmacytoma 
 No.  Time to Progress (mo)  
MGUS  1  52  
Solitary Plasmacytoma  5  Mean-52(Range: 44-65)  




ISS (n=209)  No. (%)  
I 53(25.4%)  
II 68(32.5%)  
III 88(42.1%)  




























ISS-International staging system, DSS-Durie-Salmon Staging 






 Table-14. Thalidomide-Dexamethasone-Treatment characteristics 
Thalidomide-dexamethasone 
No. of Cycles  
N=225(17 pts lost to f/u) 
Median no. of cycles-7(Range-1 to 27)   
Mean no. of cycles-8  
Thalidomide dose  No. (%) 
Median dose-200mg OD (range-50mg to 400mg OD)   
Mean dose-159.5mg OD  
≤100mg/day 87(36) 
>100mg up to 200mg/day  153(63.2)  
>200mg/day  2(0.8) 
Dexamethasone dosage   
Median: 40 mg OD (Range: 8 – 40 mg OD)  
Mean: 31.45 mg OD  
             OD-Once daily 
Table-15.DVT prophylaxis 
DVT Prophylaxis  Number  
Total-242  
Aspirin 75mg 217  
Sintrom*  1 
Clopidogrel 1 
Nil 23  
           DVT-Deep vein thrombosis 








Biphosphonate use  Number  
Total-242  
Yes 173(71.5%)  
No  69(28.5%)  
 
Table-17. Initial response to TD 
Total no. of patients initiated on TD  242  
Lost to follow up 17  
No. of patients available for response assessment 225  
CR  10(4.5%)  
CRu  10(4.5%)  
VGPR  70(31.1%)  
PR  91(40.4%)  
NR  44(19.5%)  
No. of patients responding to TD  181(80.5%)  
≥VGPR  90(40.1%)  
PR 91(40.4%)  
Median Time to respond  3mo (1-13 mo)  
No. of patients progressed post TD  153(68%) 
Time to progress after initiation of TD  
Median  11 months(1-86) 
Mean 10 months 
TD-Thalidomide-Dexamethasone, CR-Complete remission, Cru-Complete response unconfirmed,                                             
VGPR-Very good partial response, PR-Partial response, NR-No response, mo-months 
 
 70
Table-18. Response to TD according to ISS and DSS  
ISS  CR/Cru  VGPR  PR  NR  
I (n– 53)  6(11.3%)  14(18.8%)  23(43.4%)  8(15.1%)  
II (n-68)  7(10.2%)  20(29.4%)  24(35.2%)  13(19.1%)  
III (n-88)  4(4.5%)  29(32.9%)  28(31.6%)  16(18.9%)  
DSS      
I (n-31)  2(6.4%)  5(16.1%)  15(48.3%)  8(25.8%)  
II (n-86)  6(6.9%)  28(32.5%)  35(40.6%)  14(16.2%)  
III (n-125)  12(9.6%)  37(29.6%)  41(32.8%)  22(17.6%)  
TD-Thalidomide-Dexamethasone, ISS-International staging system, DSS-Durie-Salmon Staging,  CR-  
Complete remission, CRu-Complete response unconfirmed, VGPR-Very good partial response,     PR-         
Partial response, NR-No response. 
Table-19.Overall Survival according to ISS/DSS 
ISS  Alive at last f/u no. (%)  Median f/u, (range)  
I (n=51)  46(90.1)  22.5 mo (3-74 mo)  
II (n=64)  51(79.6)  26 mo (4-89 mo)  
III (n=77)  56(72.7)  28 mo (1-86 mo)  
DSS  Alive at last f/u no.(%) Median f/u, (range) 
I(n=30)  26(86.6) 20 mo (5-76 mo) 
II (n=83)  66(79.5) 25 mo (1-96 mo) 
III (n=112)  88(78.5) 25.5 mo (3-89 mo) 





Table-20. Thalidomide maintenance post TD induction 
Duration of Thalidomide maintenance post induction  
No. of  patients receiving maintenance therapy* 49  
Range 2-69 months 
Median 8 months 
Mean 14 months 
Dose of Thalidomide during maintenance   
Median dose  100mg OD (50 -200) 
TD-Thalidomide-Dexamethasone, *1 patient received Lenalidomide maintenance. 
Table-21. Deep vein thrombosis & pulmonary embolism 
Site of Thrombosis Thalidomide 
continued 
(Yes/No) 
Right common iliac, external iliac and common femoral vein No 
Chronic pulmonary thromboembolism No 
Left  common iliac, external  iliac, common femoral and 
superficial femoral veins 
Yes 
CVT#  Yes 
Chronic DVT of left common femoral vein* Yes 
B/L  infra renal IVC, right external  iliac veins Yes 
Left common femoral vein$  Yes 
      *presentation at diagnosis,  
         $Polycythemia vera - JAK 2 mutation positive 
        #Not on aspirin prophylaxis 
      DVT-Deep vein thrombosis, CVT-Cortical venous thrombosis and IVC-Inferior Vena Cava. 
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Table-22. Adverse effects of Thalidomide-Dexamethasone 
Adverse effects  Number(%) 
Total-225  
Neuropathy  48(21.3) 
Constipation  50(22.2)  
Somnolence 5(2.1)  
Rash  5(2.1) 
DVT  6(2.6) 
Hyperglycemia 28(12.4)  
Infection 4(1.5)  
Grade 4 myopathy  1(0.4)  
Depression 1(0.4)  
Cushings syndrome 1(0.4)  
syncope  1(0.4)  
Seizures  1(0.4)  
Pancreatitis  1(0.4) 
Neutropenia  1(0.4) 










 Table-23.Autologous stem cell transplantation characteristics 
Total no. of ASCT – 29 
Upfront post TD induction-13 
Post relapse/Progressive disease-16  
Median(range)  
Median age, (range)   50yrs(29-59) 
Median time from diagnosis to ASCT, mo  12 (range:4-32) 








Melphalan dose, median mg/m2  200(100-200)$  
Cell dose  
CD 34 x 106 cells/kg  





Grade I  
Grade II  
Grade III  






Time to ANC >500/cu.mm, days  
Time to ANC >1000/cu.mm, days  




G-CSF Support, days  6(4-16) 
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Table-23. Autologous stem cell transplantation characteristics –continued 
No. of days of fever  
No. day of antibiotics  
3(1-16) 
12(5-21) 
Duration of f/u post ASCT, months  15(1-74) 
No. pts with progressive disease post ASCT  




No. of patients with post transplant maintenance 
Thalidomide  
Lenalidomide  
Dose of Thalidomide, mg OD  




























TD-Thalidomide-Dexamethasone, CR-Complete remission, CRu-Complete response  unconfirmed,                                             
VGPR-Very good partial response, PR-Partial response, PD-progressive disease, MNC-Mononuclear        
cell count, ANC-Absolute neutrophil count,G-CSF-Granulocyte colony stimulating factor,ASCT-  




Table-24. Second line therapy 
No.of patients changed to second line therapy         143  
Time to second line therapy   
Median (range) 9 months (1-63) 
Mean 15 months 
Second line therapy post relapse/ PD  No. (%)  
Cyclo-Dex/Cyclo-Pred  15(10.4%)  
CTD  89(62.2%)  
MP/MPT  12(8.3%)  
LD/LLD  7(4.8%)  
PAD  10(7%)  
TD  8(5.5%)  
DVD 1(0.7%) 
HDD 1(0.7%) 
PD-Progressive disease, Cyclo-Dex- Cyclophosphamide + Dexamethasone, Cyclo-Pred- 
Cyclophosphamide + Prednisolone, CTD- Cyclophosphamide + Thalidomide + Dexamethasone, MP-
Melphalan + Prednisolone, MPT – Melphalan + Prednisolone + Thalidomide, LD – Lenalidomide + 
Dexamethasone, LLD – Lenalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone, PAD – 
Bortezomib + Adriamycin + Dexamethasone, TD – Thalidomide + Dexamethasone. DVD – Doxorubicin, 








Table 25. Statistical analysis 




PFS OS Post ASCT 
Response 
Age  0.767 0.274 0.684 0.607 - 
Sex, M vs. F  1.000 1.000 0.173 0.461 0.182 
Thalidomide Dose ≤100 vs. >150- 200 
vs. >200mg  
0.780 0.114 0.256 0.148 0.208 
Hb <10 vs. ≥10g%  0.867 0.474 0.195 0.45 0.301 
Ca <10.5 vs. >10.5mg%  0.533 0.371 0.288 1.000 0.710 
Cr <2 vs. >2 mg%  0.675 0.577 0.110 0.216 0.889 
Bone involvement  
Y vs. N  
0.380 0.842 0.853 1.000 0.546 
Plasmacytoma Y vs. N  0.847 0.232 1.000 1.000 0.196 
BM % Plasma cells  
<50, >50  
0.704 0.498 0.327 1.000 0.546 
M Band level <3, 3-5, 
 5-7, >7  
0.384 0.601 0.617 0.858 0.471 
Myeloma type 
Heavy chain vs. light chain+Non 
secretory  
0.130 0.071 0.715 0.671 0.182 
Ur BJP Positive / Negative  0.486 1.000 0.650 0.860 1.000 
24 hr urine protein <200, >200mg/d  0.110 1.000 0.658 1.000 1.000 
ISS  0.749 0.728 0.071 0.055 0.709 
DSS  0.510 0.163 0.967 0.610 0.601 
CR+CRu vs. VGPR vs. PR  - - 0.000 0.232 - 
ASCT vs. Maint. Vs. No ASCT/Maint  - - 0.0000 0.1064 - 
TD-Thalidomide-Dexamethasone,CR-Complete remission, CRu-Complete response  unconfirmed,VGPR- Very good 
partial response, PR-Partial response, OS-Overall survival, PFS-Progression free survival, BJP- Bence Jones Protein, 
ASCT-Autologous stem cell transplantation, ISS-International staging system, DSS-Durie Salmon staging, 
 
 77
Table 26. Comparison of various TD trials with the present study. 
    After induction After ASCT Regimen 
(No. Of pts) 
CR+PR% CR/≥VGPR% CR+PR % CR/≥VGPR%
PFS OS Ref. 
TD (50) Phase 
II 
















TD (71)  PhII 66 8/17 NR NR NR NR (83)  






























TD (100) VS 


























































































































ASCT-Autologous stem cell transplantation, PFS-Progression free survival, OS-Overall survival, CR-Complete response, PR-
Partial response, VGPR-Very good partial response, TD-Thalidomide+Dexamethasone, VAD-
Vincristine+Adriamycin+Dexamethasone, DASCT-Double Autologous stem cell transplantation, NR-Not reported, TTP-Time to 
progression, TAD-Thalidomide+Adriamycin+Dexamethasone, Dexa-Dexamethasone, TT-Total therapy, Thal-Thalidomide, mo-
months, MP – Melphalan-Prednisolone, ASCT – Autologous stem cell transplantation group, Maint – Thalidomide 










• Date of Diagnosis: 
• Base line Characteristics 
– CBC profile 
– Sr.Cr  
– Sr.Ca  
– Total Protein 
– Sr.Albumin 
– LDH 
– Β2 microglobulin  
– M Band 
– Urine BJP 
– 24 hour urine Protein 
– Sr.Free Light Chain Assay 
– Sr.Immunofixation Electrophoresis 
– Skeletal survey 
– Bone marrow plasma cell % 
– DSS/ISS staging 
• Date of Initiation of therapy 
• Treatment outcome 
– Response status at follow up visit 
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– Duration of treatment 
– Maximum Tolerated doses of  
• Thalidomide 
• Dexamethasone 
– Adverse effects 
– Time to response 
– Time to progression 
– Time to Change therapy 
– Time to transplant 
– Status at last visit 
 
• Maintenance yes/no 
– Date of initiation 
– Dose 
– Duration 
– Time to progress 
– Time to change therapy 
– Status at last visit 
 
• ASCT   Yes/No 
– Date of transplant 
– Melphalan Dose 
– Pretransplant status of disease 
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– Post transplant status of disease 
– Cell dose 
– Engraftment 
• ANC >500 
• Platelet count >20000 
– Infection 
– Mucositis 
– Post Transplant maintenance 
– Time to relapse/Progress 
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Expansion of codes used in Master chart 
SAD Symptoma at diagnosis RES Best response to TD 
DOD Date of diagnosis PD Progressive disease 
AGE Age at diagnosis TTP Time to progression 
DOS Duration of symptoms in 
months 
ADD Tt Number of additional 
therapiestherapy 
SP/M Past history of solitary 
plasmacytoma or MGUS 
STATUS Status of myeloma at last contact 
Hb Haemoglobin A/D/L Alive, Dead or lost to follow up at last 
contact 
PL Platelets Last 
VISIT 
Date of last visit 
TC Total WBC count 2nd TT Second line therapy 
Ca Serum Calcium Maint Thalidomide maintenance 
Cr Serum Creatinine START 
MAINT 
Date of starting maintenance post TD 
ALB Serum Albumin STOP 
MAIN 
Date of stopping maintenance post 
TD 
Bone Bone involvement Main Do Maintenance Thalidomide dose 
PCM Plasmacytoma DVT Deep vein thrombosis 
UA Serum Uric acid ABMT Autologous bone marrow transplant 
LDH Serum Lactate dehydrogenase TTT Time from diagnosis to transplant 
M M band Pre Tx Status of myeloma pretransplant 
BM% BM plasma cell % NOC Number of prior chemotherapies pre 
transplant 
B2M Beta 2 microglobulin Mel Melphalan dose 
ISS International staging system MUC Grade of Mucositis 
DSS Durie Salmon staging MNC Mono nuclear cell dose  
BJP Urine Bence Jone Protein CD34 CD 34 cell dose 
24HUP 24 hour urine protein ANC1 No. of days to ANC increase >500 
MM Type of Multiple Myeloma ANC2 No. of days to ANC increase >1000 
THAL 
START 
Date of starting TD PL1 No. of days to platelets >20000 
THAL 
STOP 
Date of stopping TD GCSF No. of days of GCSF support 
DOT Thalidomide dose Fever No. of days of fever post transplant 
DDO Dexamethasone dose ABD No. of days of antibiotics 
CY Number of cycles of TD PTS Post ASCT status of myeloma 
ASP Aspirin prophylaxis PTPD Post transplant progressive disease 
BIP Bisphosphonate  PTRD Post transplant relapse date 
PN Peripheral neuropathy PTM Post ASCt maintenance 
CON Constipation PTMD Post transplant maintenance duration 
SOM Somnolence PTMDo Post transplant maintenance dose of 
Thalidomide 
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TTR Time to respond to TD LTF Lost to followup 
PR Partial response VGPR Very good partial response 
NR No response CR Complete response 
CRu Complete response 
unconfirmed 
TD Thalidomide dexamethasone 
 
Interpretation of codes used for individual parameters 

















Second line therapy 
CP – Cyclophosphamide + Prednisolone 
CD - Cyclophosphamide + Dexamethasone 
TD – Thalidomide + Dexamethasone 
MP – Melphalan + Prednisolone 
MPT - Melphalan + Prednisolone 
 + Thalidomide 
LD – Lenalidomide + Dexamethasone 
LLD - Lenalidomide + Dexamethasone + 
Pegylated lipodoxorubicin 
PAD – Bortezomid + Adriamycin + 
Prednisolone 
DVD – Doxorubicin + Vincristine + 
Dexamethasone 
HDD – High dose dexamethasone 
Hb 
1 <10 g/dl 
2≥10 g/dl 
Dose of Thalidomide 
1 - ≤100 mg per day 
2 - >100mg to ≤200mg per day 















1 - Cr<2 
2- Cr>=2 
3-NA/ND 









Y – ASPIRIN 
N – NO 
C – Clopidogrel 








NA- Not available 
 
AE – Adverse effect of Thalidomide 
Dexamethasone 
0 – No 
1 – Yes 
1 – Hyperglycemia 
2 – Cushing syndrome 
3 – Grade IV myopathy 
4 – Infection 
5 – Somnolence 
6 – Neutropenia 
7 – Rash 
Maint – Post TD induction therapy of patients 
a-ASCT 
b- Thalidomide maintenance 
c-no ASCT no main  








0 Sex DOD AGE SAD SP/M DOS Hb PL TC 
C




%  B2M DSS 
IS
S M Band MM BJP 24HUP 
AS





009 55 2 0 3 2 2 2 1 2 1 1 N NA NA 1 1 1A 1 0 5 1 3 Y Y 01/03/2009 05/27/2009 5 200 40 No 
2 M 
11/24/2
007 53 2 0 3 2 2 2 1 1 1 1 N H N 2 2 3A 2 9.6 1 2 2 Y Y 11/24/2007 03/01/2008 3 200 40 No 
3 M 
09/02/2
008 57 2 0 3 2 2 2 1 1 1 1 N H NA 2 2 3A 2 6.2 1 1 3 Y Y 09/14/2008 11/06/2009 14 200 20 No 
4 F 
06/29/2
007 62 2 0 8 2 2 2 2 2 1 1 N N H 1 2 1A 2 0 7 2 3 Y Y 07/03/2007 07/04/2008 12 200 20 y 
5 M 
02/05/2
008 55 3,15 0 3 1 2 2 2 2 2 0 N NA H 1 3 2B 3 0 5 1 2 Y N 02/05/2008 06/30/2009 17 200 40 No 
6 M 
04/08/2
011 58 5 0 2 2 1 2 2 2 2 1 Y H H 2 3 3B 3 2.48 1 1 3 Y Y 04/08/2011 08/16/2011 4 100 20 No 
7 F 
10/15/2
010 32 1,2, 6 0 3 1 2 2 1 1 1 1 N H N 2 2 3A 2 6 2 1 2 Y Y 10/20/2010 04/29/2011 6 150 40 No 
8 M 
04/17/2
006 50 2 0 2 2 2 2 1 2 1 0 N N N 1 1 1A 1 4.6 1 1 1 Y Y 05/29/2006 02/02/2007 8 200 40 No 
9 M 
07/01/2









12 0 6 2 2 2 1 2 1 1 N H NA 2 2 2A 2 1.4 1 1 2 Y Y 08/06/2010 02/01/2011 6 150 20 No 
12 M 
02/26/2
008 35 2,5 0 15 1 2 2 1 1 1 1 N N H 2 3 2B 3 11.24 1 1 2 Y Y 03/03/2008 05/09/2008 2 200 40 No 
13 M 
01/29/2
008 56 2,7 0 6 2 2 2 1 2 1 1 N H N 2 1 2A 1 0.8 1 1 1 Y Y 01/29/2008 07/29/2008 6 150 20 y 
14 M 
10/23/2
010 56 7 0 0.5 2 2 2 1 2 1 1 N NA NA 1 1 1A 1 3.37 1 2 2 Y Y 11/05/2010 05/27/2011 7 150 20 No 
15 M 
05/18/2
007 63 2 0 4 1 2 2 1 1 1 1 N N H 2 3 3A 3 4.8 2 1 2 Y Y 05/29/2007 10/17/2008 17 100 40 No 
16 M 
08/11/2
007 47 1,3 0 1 1 1 2 1 1 2 1 N N H 1 3 3B 3 2.5 1 1 2 Y Y 08/21/2007 06/16/2008 10 200 40 No 
17 F 
07/09/2
010 48 2 0 2 2 2 2 1 2 1 1 N N H 2 2 1A 2 5.6 1 1 3 Y Y 07/10/2010 10/15/2010 3 150 20 No 
18 M 
10/12/2
009 78 2 0 8 2 2 2 1 2 1 1 N H NA 1 1 2A 1 2.3 1 1 3 Y N 12/08/2009 09/10/2010 9 100 20 y 
19 M 
12/15/2
005 57 5 0 1 1 2 2 1 1 1 1 N N N 1 1 2A 1 4.5 1 2 2 Y N 01/13/2006 07/01/2006 6 100 40 No 
20 M 
11/20/2
008 48 2 0 1 2 2 2 2 1 2 1 Y N NA 1 3 2B 3 6.19 1 1 2 Y N 11/26/2008 01/23/2009 2 200 40 No 
21 M 
11/04/2
008 56 2 0 18 1 2 2 1 1 1 1 N NA NA 1 2 3A 2 3.2 1 1 2 Y Y 11/04/2008 02/02/2009 3 200 40 No 
22 M 
08/02/2
008 51 2 0 3 1 2 2 1 2 2 1 N N H 1 3 2B 3 4.5 1 1 2 Y Y 07/27/2008 08/27/2008 1 200 40 No 
23 M 
06/25/2
011 58 2,7 0 3 2 2 2 1 2 1 1 Y H H 1 1 1A 1 3.35 1 3 3 Y Y 06/27/2011 12/02/2011 5 200 40 No 
24 M 
02/16/2
007 29 14 0 3 2 2 2 1 2 1 1 Y NA NA 2 2 2A 2 0 5 1 3 Y N 02/16/2007 03/07/2008 13 100 40 No 
25 M 
02/01/2
006 64 10 0 1 1 2 2 1 1 2 0 N N H 1 3 3B 3 3.3 1 1 2 Y Y  02/20/2006 07/21/2006 5 200 40 No 
26 F 
09/01/2
008 80 2 0 2 1 1 1 1 1 1 1 N N N 2 2 2A 2 3.5 1 2 1 Y N 09/05/2008 11/04/2008 2 100 20 No 
27 F 
04/11/





4 0 7 1 2 2 2 1 2 1 N N H 1 4 3B 4 4.8 1 1 1 Y Y 12/07/2006 07/06/2007 7 200 40 y 
29 M 
09/22/2
009 55 2 0 6 2 2 2 2 2 1 1 N NA N 2 3 3A 3 5.85 1 1 2 Y Y 09/22/2009 09/17/2010 12 200 20 y 
30 M 
07/01/2
005 49 2 0 2 2 2 2 1 1 1 1 N N H 2 3 1A 3 7.2 1 2 3 N N 07/01/2005 01/24/2006 7 200 40 No 
31 F 
09/19/2





7 0 3 1 2 2 2 1 2 1 Y H H 1 3 3B 3 6.65 1 1 3 Y Y 09/16/2005 09/16/2006 12 100 40 No 
33 M 
05/11/2
009 54 14 0 12 2 2 2 1 2 1 1 Y NA NA 2 4 2A 4 0.51 4 2 1 Y N 05/19/2009 12/01/2009 7 100 20 No 
34 M 
07/02/2
006 61 14 0 3 2 2 2 1 2 1 1 Y N H 1 4 2A 4 2 2 2 3 Y Y 07/20/2006 01/31/2007 7 200 20 y 
35 M 
10/01/2
006 58 2 0 2 1 2 2 2 1 2 1 N N H 1 3 3B 3 3.3 2 1 3 Y  N 10/01/2006 03/02/2007 5 200 20 No 
36 F 
02/25/2
011 50 2 0 2 2 2 2 1 2 1 1 Y N NA 1 1 2A 1 2 1 2 1 Y Y 03/04/2011 09/30/2011 7 150 20 No 
37 M 
06/24/2
005 53 1,2,3 0 5 1 2 2 1 2 2 1 N NA H 1 3 3B 3 0 5 1 2 N Y 07/09/2005 04/01/2006 9 200 40 No 
38 M 
11/18/2
008 68 14 0 4 1 2 2 1 1 1 1 Y N N 1 3 2A 3 4.93 2 1 2 Y Y 11/23/2008 02/24/2009 3 150 40 No 
39 M 
08/21/2
008 59 14 0 1 1 2 2 1 1 2 1 Y NA H 1 3 2B 3 4.5 1 1 2 Y N 08/30/2008 10/26/2008 2 150 20 No 
40 M 
11/21/2
008 37 2,8  0 5 1 2 2 2 2 2 1 N H H 2 3 3B 3 
BICLO
NAL 6 2 2 Y N 11/25/2008 01/06/2009 1 200 20 y 
41 M 
11/10/2
005 56 1,2,3 0 3 1 2 2 1 2 2 1 Y N H 1 3 3A 3 1.63 1 1 2 Y N 02/17/2006 10/24/2006 8 200 40 No 
42 M 
05/10/2
011 41 2 0 1 2 1 2 1 2 1 1 N NA H 2 3 2A 3 5 2 1 3 Y Y 05/10/2011 12/06/2011 7 100 40 No 
43 F 
09/11/2
006 48 2 0 2 1 2 2 2 1 1 1 N N H 2 2 2A 2 5.75 2 2 2 Y Y 09/20/2006 04/24/2007 7 200 40 No 
44 M 
03/17/2
009 52 2 2 13 2 2 2 1 2 1 0 N N NA 1 1 1A 1 3.06 1 3 3 Y N 03/17/2009 08/06/2010 17 100 20 No 
45 M 
12/15/2
009 52 9 0 3 2 2 2 1 1 1 1 N N NA 1 2 3A 2 6.6 1 1 2 Y Y 12/15/2009 06/04/2010 6 100 20 No 
46 M 
01/17/2
008 46 2,3 0 1 2 2 2 2 2 2 1 N H NA 1 3 2B 3 0 5 1 2 Y Y 02/02/2008 05/30/2008 4 100 40 No 
47 M 
08/14/2




008 53 1,3 0 2 1 2 2 1 2 2 0 N N N 1 3 3B 3 1.6 1 1 2 Y N 09/25/2008 11/04/2008 1 200 20 No 
49 M 
06/25/2
006 54 16 0 1 1 2 2 2 1 1 0 N NA NA 1 4 2A 4 3.5 1 2 1 S Y 04/10/2007 08/03/2007 4 100 40 No 
50 M 
01/18/2
010 49 2 0 0.5 2 2 2 1 2 1 1 N N N 1 1 1A 1 3.3 1 2 3 Y N 01/20/2010 04/20/2010 3 200 20 No 
51 M 
12/08/2
008 68 14 0 2 2 2 2 1 2 1 1 Y H N 1 4 2A 4 1.5 1 2 3 Y N 12/08/2008 06/19/2009 6 200 20 No 
52 F 
03/04/2
008 55 1 0 7 2 2 2 1 2 1 1 N H N 1 3 1A 3 1.99 1 2 2 Y Y 03/07/2008 09/12/2008 6 100 40 y 
53 M 
05/23/2
008 65 2 0 1 1 2 2 1 1 1 1 N N N 2 2 3A 2 7.21 1 1 3 Y Y 05/27/2008 09/12/2008 4 100 40 y 
54 F 
09/14/2
007 52 1,2 0 5 2 2 2 1 2 1 1 N N NA 1 1 1A 1 2.7 1 2 1 Y Y 09/18/2007 01/15/2008 4 200 40 No 
55 F 
06/23/2
005 62 1,2,3 0 12 1 2 2 1 2 2 1 N N H 1 3 3B 3 FAINT 5 1 2 Y N 06/28/2005 01/12/2007 19 100 40 No 
56 M 
01/30/2
006 59 1,5 0 2 1 2 2 1 2 2 0 N N H 2 3 2B 3 3.1 1 1 2 Y N 02/10/2006 06/26/2006 5 150 40 No 
57 M 
02/23/2
008 56 2 0 2 2 2 2 1 2 1 1 N N N 1 1 2A 1 0 5 2 1 Y Y 03/02/2008 09/02/2008 6 200 20 No 
58 M 
08/07/2
005 39 9 0 1 2 2 2 1 2 1 1 Y NA NA 1 4 2A 4 0 5 3 3 Y Y 08/07/2009 05/03/2010 9 200 40 No 
59 M 
07/01/2
009 54 14 0 1 2 2 2 1 2 1 1 Y NA NA 1 4 2A 4 0 5 1 3 Y Y 07/17/2009 03/23/2010 8 100 20 No 
60 F 
02/05/2
007 52 1,3 0 3 1 2 2 1 1 2 1 N N N 1 3 3B 3 0 5 1 3 Y N 02/15/2007 10/15/2007 8 200 40 No 
61 M 
06/15/2
011 62 2 0 2 2 2 2 1 2 1 1 N N N 1 4 3A 4 0 5 2 3 Y Y 07/22/2011 11/18/2011 4 200 20 No 
62 M 
02/19/2
007 61 2 0 4 1 2 2 1 1 1 1 N N N 1 2 2A 2 5.6 1 1 2 Y N 02/20/2007 08/20/2007 6 150 40 No 
63 F 
10/04/2
005 55 1 0 6 1 2 2 2 2 2 1 N N NA 1 3 3B 3 0.8 5 1 2 Y Y 10/11/2005 03/28/2006 6 200 40 No 
64 M 
01/07/2
010 59 6,14 0 2 2 2 2 1 2 1 1 Y H NA 1 4 2A 4 0 5 3 3 Y Y 01/19/2010 09/18/2010 8 150 40 y 
65 F 
08/09/2
006 57 2,9 0 6 1 2 2 2 2 1 1 N N H 1 1 2A 1 3.2 1 2 3 Y  Y 08/20/2006 12/07/2007 16 100 20 No 
66 M 
05/31/2
005 21 7 0 1.5 2 2 2 1 1 1 1 Y N H 1 4 2A 4 3.75 4 2 3 N Y 07/10/2005 01/17/2006 6 200 40 No 
67 M 
07/28/2
010 57 8, 0 6 2 2 2 1 2 1 1 N N N 1 1 2A 1 2.8 2 1 3 Y Y 07/28/2010 05/10/2011 10 200 20 No 
68 M 
09/14/2
007 50 2,10 0 4 2 2 2 1 2 1 1 N NA NA 1 1 1A 1 2.4 4 2 2 Y Y 09/14/2007 12/21/2007 3 100 40 No 
69 M 
04/26/2
008 47 2 0 2 1 2 2 1 1 1 1 N N H 1 3 3A 3 8 1 2 3 Y Y 05/10/2008 12/02/2009 19 100 40 No 
70 F 
07/07/2
009 42 1,2 0 4 2 2 2 1 2 1 1 Y NA N 1 1 3A 1 FAINT 1 2 2 Y Y 07/07/2009 10/15/2010 16 100 20 y 
71 F 
08/05/2
011 43 2,9 0 3 1 2 2 2 1 2 1 N N H 1 3 3B 3 
BICLO
NAL 6 1 2 Y Y 08/20/2011 12/23/2011 4 200 40 y 
72 M 
01/20/2
006 61 14 0 8 2 2 2 1 2 1 1 Y N NA 1 2 2A 2 2.4 2 1 2 Y Y 01/20/2006 05/20/2007 16 100 40 No 
73 M 
08/26/2
008 66 1,2 0 12 1 2 2 1 1 1 0 N N NA 1 1 2A 2 2 4 2 3 Y Y 08/26/2008 07/28/2009 11 100 20 No 
74 F 
02/03/2
009 32 1,2 0 2 1 2 2 1 1 1 1 N N H 1 1 3A 2 8.4 1 2 2 Y Y 02/06/2009 08/21/2009 7 150 20 No 
75 F 
07/30/2
004 50 1,8 0 4 1 2 2 1 2 1 1 N NA NA 2 3 3A 3 3.5 1 1 3 Y Y 07/30/2004 06/28/2005 11 200 40 No 
76 M 
07/27/2
007 62 1 0 2 1 2 2 1 2 1 1 N N H 2 2 2A 2 0 5 2 2 Y Y 08/03/2007 05/26/2009 22 200 40 y 
77 M 
11/16/2
010 69 3 0 1 1 2 2 1 1 2 1 N NA NA 1 3 2B 3 
BICLO
NAL 6 1 2 Y Y 11/16/2010 03/29/2011 4 100 40 No 
78 M 
02/17/2
006 54 5 0 12 1 2 2 1 1 1 0 N H H 1 4 2A 4 4.5 1 1 1 Y N 03/03/2006 08/31/2006 6 200 40 No 
79 M 
04/06/2
011 58 9 0 6 2 2 2 2 1 1 1 Y NA NA 1 1 1A 2 4 1 1 3 Y Y 05/07/2011 12/07/2011 7 100 20 No 
80 F 
11/03/2
009 65 2 0 1 2 2 2 1 2 1 1 N H N 1 1 1A 1 3.1 1 2 1 Y Y 11/03/2009 04/30/2010 6 200 20 No 
81 M 
11/02/2
007 61 2 0 3 2 2 2 1 2 1 1 N H H 1 1 2A 1 1.8 1 2 2 Y N 11/13/2007 07/22/2008 8 150 40 y 
82 F 
09/07/2
010 45 12 0 3 1 1 1 1 1 1 1 N N N 2 4 3A 4 5.49 1 1 3 Y N 09/07/2010 03/01/2011 6 100 20 No 
83 M 
07/12/2
007 66 1 0 3 2 1 1 1 1 1 0 N N NA 1 2 1A 2 3.4 2 1 2 Y Y 07/17/2007 09/12/2008 14 100 40 No 
84 M 
05/27/2
011 54 2 0 2 2 2 2 1 2 1 1 Y H N 1 1 3A 1 0.6 1 2 3 Y Y 04/18/2011 09/06/2011 5 200 40 No 
85 M 
08/17/2
006 55 1,2 0 6 1 2 2 1 2 2 1 Y NA N 1 3 3B 3 0 5 2 2 y Y 08/22/2006 12/08/2006 4 100 40 y 
86 F 
03/02/2
004 53 2 0 2 2 2 2 1 2 1 1 N NA N 1 2 2A 2 1.3 1 2 3 N Y 03/05/2004 10/05/2004 7 200 40 No 
87 M 
10/10/2
006 44 14 1 25 2 2 2 1 2 1 1 Y N NA 1 1 2A 1 3.1 4 2 3 Y Y 10/13/2006 08/21/2007 10 200 40 y 
88 M 
08/11/2
009 67 1,5 0 18 1 2 2 1 1 1 0 N H N 1 2 3A 2 3.21 1 1 3 Y Y 09/04/2009 07/21/2010 11 150 20 y 
89 F 
01/12/2
007 57 1 0 3 1 2 2 1 1 1 1 N N N 1 3 3A 3 6.5 2 1 2 Y Y 08/18/2006 03/02/2007 7 200 40 y 
90 M 
11/28/2
008 52 2, 14 0 0.5 2 2 2 1 2 1 1 Y H N 1 2 2A 2 1.5 2 2 2 Y Y 12/01/2008 05/23/2009 6 200 20 No 
91 M 
07/11/2
005 66 1 0 6 1 2 2 1 1 1 0 N N H 1 3 3A 3 6.3 1 1 3 N N 07/11/2005 02/11/2006 7 200 40 No 
92 F 
01/17/2
006 64 1,2 0 2 1 2 2 1 2 1 1 N N N 1 4 3A 4 0.95 4 1 3 Y N 02/17/2006 11/10/2006 9 100 40 No 
93 F 
11/11/2
009 64 1,5 0 3 1 2 2 1 2 1 1 N N N 1 1 3A 1 6 1 1 3 Y Y 11/11/2009 12/14/2010 13 200 20 No 
94 M 
10/10/2
007 54 2,8 0 6 1 2 2 2 1 1 1 N N H 1 3 3A 3 4.16 1 1 3 Y Y 10/10/2007 11/14/2008 13 200 20 y 
95 M 
08/20/2




010 38 2 0 36 2 2 2 1 2 1 1 N N NA 1 4 3A 4 0 5 2 2 Y Y 03/16/2010 03/15/2011 12 100 20 No 
97 M 
04/28/2
007 41 1,2 0 18 1 2 2 2 1 1 1 N N N 1 3 3A 3 9.5 1 1 3 Y Y 06/22/2007 01/04/2008 7 200 40 No 
98 F 
02/18/2
010 50 2, 7 0 1 2 2 2 1 2 1 1 Y N N 1 1 1A 1 FAINT 5 1 3 Y Y 03/09/2010 12/16/2010 9 200 20 No 
99 F 
12/12/2
008 55 2 0 3 1 2 2 2 1 2 1 N N NA 1 3 3B 3 3.5 6 1 2 Y Y 12/12/2008 03/13/2009 3 200 20 y 
100 M 
11/12/2
010 59 2 0 4 1 2 2 1 1 2 1 N N H 1 4 3B 4 4.7 1 1 3 Y Y 11/12/2010 08/19/2011 9 100 20 No 
101 M 
06/07/2
010 49 2 0 3 2 2 2 1 1 1 1 N N H 1 2 3A 2 6 1 1 3 Y Y 06/08/2010 12/08/2010 6 200 20 No 
102 F 
06/25/2
008 61 1 0 12 1 2 2 1 2 1 0 N N N 1 3 2A 3 
BICLO
NAL 6 2 1 Y Y 06/25/2008 07/15/2009 13 200 20 y 
103 F 
11/18/2
006 38 2 0 0.5 1 2 2 2 1 2 0 N N H 2 3 3B 3 11.2 1 1 2 Y  Y 11/28/2006 09/28/2007 10 200 40 No 
104 M 
09/08/2
008 42 2,8,14 0 6 2 2 2 1 2 1 1 N N N 1 1 1A 1 1.3 1 2 3 Y Y 09/26/2008 04/03/2009 6 200 20 No 
105 M 
01/23/2
007 65 2 0 1 2 2 2 1 2 1 1 N N NA 1 1 2A 1 0.3 2 3 3 Y Y 02/13/2007 11/13/2007 9 200 40 No 
106 M 
09/29/2
009 54 2 0 6 2 2 2 1 1 1 1 N N N 1 2 3A 2 3.2 2 2 1 Y Y 09/29/2009 02/05/2010 4 100 20 No 
107 M 
11/13/2
007 53 2 0 6 1 2 2 1 2 1 1 Y NA N 2 2 3A 2 2 2 2 1 Y Y 11/13/2007 07/20/2008 8 100 40 No 
108 M 
08/04/2
005 68 1 0 4 1 2 2 2 1 1 0 N NA H 2 3 3A 3 6.5 1 1 3 Y Y 08/23/2005 07/31/2007 24 200 40 y 
109 M 
08/28/2
007 52 1,2 0 3 1 2 2 1 1 1 1 N N H 1 2 2A 2 4 1 2 3 Y Y 08/31/2007 03/11/2008 6 100 40 No 
110 M 
10/10/2
007 31 2 0 2 1 2 2 1 2 1 1 N H NA 2 2 3A 2 5.6 4 1 2 Y Y 10/10/2007 04/20/2008 6 200 40 No 
111 M 
12/18/2
008 60 1,2,3 0 3 1 2 2 2 1 2 1 N NA N 1 3 3B 3 9.5 1 3 3 Y N 12/22/2008 06/26/2009 6 200 40 No 
112 M 
01/11/2
011 65 2 0 2 1 2 2 1 1 1 1 Y NA N 1 1 2A 2 3.8 1 2 3 Y Y 01/18/2011 07/15/2011 6 150 20 y 
113 F 
06/10/2
008 60 2 0 3 1 2 2 1 2 1 1 N NA H 1 3 3A 3 2.5 1 1 2 Y Y 06/15/2008 02/13/2009 8 200 20 y 
114 M 
03/25/2
011 50 1,2 0 4 1 2 2 1 2 1 1 N N N 1 2 3A 2 2 5 1 1 Y Y 03/28/2011 09/30/2011 6 150 20 No 
115 M 
04/25/2
008 73 1,3 0 1 1 2 2 1 1 2 0 N N N 1 4 3B 4 5.3 1 1 2 Y N 04/29/2008 03/10/2009 11 150 20 No 
116 F 
02/08/2
006 47 1 0 2 1 2 2 1 1 1 0 N N NA 2 2 3A 2 7.7 1 1 3 N Y 02/08/2006 08/11/2006 6 200 40 No 
117 M 
11/07/2
006 42 11 0 12 1 2 2 1 1 1 0 N N N 1 1 2A 2 4 1 2 3 Y N 12/19/2006 07/29/2008 20 100 40 No 
118 M 
07/09/2
009 48 14 0 4 1 2 2 1 2 1 1 Y N N 1 2 3A 2 3.6 2 2 2 Y Y 08/11/2009 02/17/2010 6 100 20 No 
119 M 
08/24/2
008 49 2 0 3 2 2 2 1 2 1 1 N H N 1 1 2A 1 
Dec 
gam 5 2 1 Y Y 08/24/2008 04/08/2009 8 200 20 No 
120 M 
01/25/2
011 47 14 0 12 1 2 2 1 1 1 1 Y NA NA 1 1 2A 2 8.3 4 2 1 Y Y 01/25/2011 09/13/2011 8 100 40 No 
121 M 
12/18/2
007 41 1,2 0 0.5 1 2 2 1 1 1 1 N H NA 1 2 2A 2 1.6 1 2 2 Y Y 12/25/2007 10/21/2008 10 200 40 No 
122 M 
09/08/2
009 53 1,8 0 9 1 1 2 1 2 2 1 N H H 2 3 3B 3 2.3 1 3 2 Y N 09/18/2009 12/11/2009 3 100 20 No 
123 M 
04/04/2
008 58 2,14 0 6 2 2 2 1 1 1 1 Y N N 1 1 1A 2 7 1 3 2 Y Y 04/04/2008 01/30/2009 10 150 20 No 
124 F 
03/18/2
011 50 2,7 0 2 2 2 2 1 2 1 1 Y NA NA 2 1 1A 1 
Dec 
gam 5 1 3 Y Y 03/18/2011 09/23/2011 6 100 40 No 
125 M 
11/22/2
005 69 1, 9 0 3 1 1 1 1 1 1 1 N NA NA 1 2 3A 2 
BROA
D 3 1 2 N Y 11/30/2005 03/30/2007 16 200 20 y 
126 M 
02/17/2
006 54 1 0 2 1 2 2 1 1 1 1 N N NA 1 1 3A 2 8.5 1 3 3 Y Y 02/17/2006 LTF LTF 200 40 LTF 
127 M 
11/23/2
007 61 2 0 12 1 2 2 1 2 1 1 N H N 1 1 3A 1 3.2 1 2 1 Y Y 11/30/2007 LTF LTF 100 40 LTF 
128 M 
12/08/2
011 53 2,8 0 12 1 2 2 1 2 1 0 N NA N 1 2 3A 2 4.6 2 1 3 Y Y 12/16/2011 LTF LTF 200 20 LTF 
129 M 
04/05/2
011 60 6 0 1 1 2 2 1 1 1 1 N NA NA 1 3 3A 3 4 1 1 2 Y Y 04/06/2011 LTF LTF 100 20 LTF 
130 F 
07/01/2
011 43 3,5 0 3 1 2 2 1 1 2 0 N N N 1 3 3B 3 6 1 1 2 Y N 07/01/2011 08/02/2011 LTF 200 40 LTF 
131 M 
02/20/2





6,15 0 3 1 2 2 1 2 2 1 N NA NA 1 3 2B 3 0 5 1 2 Y N 06/03/2011 09/03/2011 LTF 100 20 LTF 
133 M 
04/18/2
005 51 2,3,4 0 1 1 2 2 2 1 2 1 N N H 1 3 3A 3 5.6 4 1 2 N N 04/27/2005 LTF LTF 100 8 LTF 
134 M 
12/09/2
008 45 2 0 12 1 2 2 1 2 1 1 N H H 1 3 2A 3 0 5 1 2 Y Y 12/12/2008 LTF LTF 200 20 LTF 
135 F 
09/30/2
011 72 2 0 12 2 2 2 1 2 1 1 N N N 1 1 1A 1 1.2 3 2 1 Y Y 10/07/2011 LTF LTF 100 20 LTF 
136 F 
07/12/2
005 36 14 0 24 2 2 2 1 2 1 1 Y N N 1 2 2A 2 0 7 2 3 N Y 07/12/2005 10/22/2005 LTF 200 40 LTF 
137 F 
11/28/2
011 55 14 0 3 2 2 2 1 2 1 1 Y H N 1 3 3A 3 0.6 5 1 2 Y Y 12/27/2011 LTF LTF 100 20 LTF 
138 M 
11/23/2
007 52 2,8 0 12 1 2 2 1 1 1 1 N N H 2 3 3A 3 FAINT 2 1 2 Y Y 12/04/2007 LTF LTF 50 40 LTF 
139 M 
06/30/2
007 43 1,3,4 0 1 1 2 2 2 1 2 1 N NA H 2 3 3B 3 5.1 1 1 2 Y N 06/30/2007 LTF LTF 100 40 LTF 
140 F 
02/01/2
009 58 1,5,8 0 12 1 2 2 1 1 2 1 N H H 2 3 3B 3 5 6 1 2 Y N 02/03/2009 LTF LTF 100 20 LTF 
141 M 
10/15/2
010 45 1,2,3 0 7 1 2 2 1 2 2 1 N N H 2 3 3B 3 1 5 1 2 Y N 02/12/2010 LTF LTF 50 20 LTF 
142 M 
06/26/2
007 72 1 0 9 2 2 2 1 1 1 1 N N N 2 3 3A 3 3.2 2 1 3 Y N 06/27/2007 LTF LTF 100 40 LTF 
143 M 
07/15/2




007 55 2 0 2 2 2 2 1 2 1 1 N NA NA 1 4 2A 4 1 4 2 1 Y Y 12/21/2007 02/29/2008 2 200 40 No 
145 F 
06/24/2
011 53 2 0 5 1 2 2 2 2 1 1 N NA N 1 1 3A 1 
Dec 
gam 5 2 1 Y Y 06/24/2011 09/27/2011 3 100 40 No 
146 F 
08/11/2
009 58 1,2,7 0 2 2 2 2 1 2 1 1 N N H 1 2 3A 2 0 5 1 2 Y Y 08/11/2009 12/22/2009 4 200 20 No 
147 F 
11/13/2
009 45 1 0 3 2 1 1 1 2 1 0 N H NA 2 1 3A 1 FAINT 5 1 3 Y Y 11/27/2009 08/17/2010 9 150 20 No 
148 F 
07/24/2
007 50 2 0 2 1 2 2 1 1 1 1 N N N 1 2 3A 2 7.2 1 1 3 Y Y 07/24/2007 02/12/2008 7 200 40 No 
149 M 
02/14/2
007 76 2,8 0 12 1 2 2 1 1 1 0 N N H 1 3 3A 3 1.54 1 2 2 C N 03/01/2007 10/31/2007 8 100 40 No 
150 F 
07/31/2
007 46 2 0 2 2 2 2 2 2 1 1 N NA H 1 2 2A 2 0.9 5 1 3 Y Y 07/31/2007 10/23/2007 3 200 40 No 
151 M 
03/08/2
011 56 2 0 2 1 2 2 1 1 1 1 N N NA 1 1 3A 2 
BICLO
NAL 2 1 2 Y Y 03/11/2011 09/05/2011 6 100 40 No 
152 F 
06/03/2
011 45 2,8 0 3 2 2 2 2 1 1 1 N N N 1 3 2A 3 5.2 1 1 3 y Y 06/10/2011 07/12/2011 1 100 40 No 
153 M 
12/04/2
009 66 1 0 6 1 2 2 1 1 1 0 N NA NA 2 3 3A 3 
BICLO
NAL 6 1 3 Y Y 12/04/2009 09/03/2010 9 100 20 No 
154 M 
04/26/2
011 53 2 0 2 2 2 2 1 2 1 1 Y H N 1 1 2A 1 1.12 1 1 3 Y Y 04/26/2011 11/04/2011 6 100 20 No 
155 F 
01/31/2
006 43 2 0 6 1 2 2 2 2 2 1 N N H 1 3 3B 3 3.4 2 1 2 Y N 01/31/2006 11/17/2006 10 200 20 No 
156 M 
01/10/2
010 55 2 0 6 2 2 2 1 2 2 1 N N H 2 4 2B 4 0 5 1 3 Y N 01/14/2010 09/07/2010 8 150 40 No 
157 M 
05/02/2
004 70 2 0 1 2 2 2 2 1 2 1 N NA NA 1 3 2B 3 3.2 1 1 3 N N 06/18/2004 02/14/2006 20 200 40 No 
158 M 
08/25/2
004 40 2, 9 0 2 1 2 2 1 1 1 1 Y N N 1 1 3A 2 5.3 1 1 3 N Y 09/28/2004 03/21/2005 6 400 40 No 
159 M 
08/03/2
006 59 12 0 24 2 2 2 1 1 1 1 N N N 1 1 2A 2 5 1 1 3 Y Y 08/18/2006 02/23/2007 6 100 40 y 
160 M 
09/05/2
006 54 2,8,14 0 1.5 2 2 2 2 1 1 1 Y N N 1 1 3A 2 4.4 1 1 3 Y Y 09/06/2006 07/03/2007 10 200 40 No 
161 F 
03/09/2
004 40 2,13 0 2 1 1 1 2 1 1 0 N NA NA 1 4 2A 4 4.5 1 1 3 N Y 03/09/2004 07/12/2004 4 200 40 No 
162 F 
09/13/2
011 60 11 0 0.5 1 2 2 1 2 1 1 Y N N 1 2 2A 1 3 1 2 1 Y Y 09/30/2011 12/27/2011 3 100 40 No 
163 M 
04/19/2
010 52 2 0 2 2 2 2 1 1 1 1 N N N 1 1 1A 2 1.59 1 2 2 Y Y 04/25/2010 12/10/2010 8 150 20 No 
164 M 
12/05/2
006 71 1 0 12 1 2 2 1 2 1 1 N H NA 1 3 3A 3 2.55 1 2 1 Y N 03/02/2007 09/08/2007 6 100 40 No 
165 M 
03/24/
2006 53 1 0 48 1 2 2 1 1 1 0 N N N 1 2 2A 2 1.16 5 1 2 Y N 04/07/2006 10/27/2006 7 200 40 No 
166 F 
05/31/2
006 56 14 0 3 2 2 2 1 2 1 1 Y NA NA 1 2 1A 2 1.4 2 2 3 Y Y 06/02/2006 11/28/2006 6 200 40 No 
167 M 
05/20/2
005 51 14 1 6 1 2 2 1 2 1 1 Y NA NA 1 1 2A 1 0 7 2 3 N Y 06/03/2005 12/03/2005 6 200 40 No 
168 F 
01/22/2





10 0 18 1 2 2 1 2 1 1 N NA N 1 3 3A 3 0.25 1 2 3 Y Y 11/18/2008 01/08/2010 14 200 20 No 
170 M 
10/13/2
008 54 2 0 2 1 2 2 1 2 1 1 N N NA 1 1 2A 1 4.9 3 1 1 Y Y 10/25/2008 05/01/2009 6 200 20 y 
171 M 
12/03/2
010 31 2 0 6 2 2 2 1 2 1 1 N N N 1 1 2A 1 0 5 1 2 Y Y 12/09/2010 08/22/2011 9 200 40 No 
172 M 
03/21/2
011 31 2 0 3 1 2 2 1 1 1 1 N NA N 1 4 3A 4 7.42 1 1 3 Y Y 03/30/2011 10/11/2011 7 200 40 No 
173 M 
01/11/2
011 63 1 0 6 1 1 2 1 2 1 0 N H NA 2 3 3A 3 0 5 1 2 Y N 01/14/2011 08/02/2011 7 150 40 y 
174 M 
12/18/2





4  0 18 2 2 2 1 2 1 1 Y N N 1 1 2A 1 4.5 1 2 1 Y N 05/10/2008 12/23/2008 8 100 40 No 
176 F 
06/21/2
011 50 1,5 0 6 1 2 2 1 2 1 0 N N NA 1 3 3A 3 FAINT 1 1 2 Y N 06/21/2011 10/30/2011 4 100 40 No 
177 F 
11/04/2
008 68 1,2 0 12 1 2 2 1 1 1 1 N N N 1 3 3A 3 9.7 3 1 2 Y N 11/04/2008 08/31/2010 22 100 20 y 
178 M 
05/02/2
008 43 2 0 6 2 2 2 1 2 1 1 N N N 1 1 1A 1 FAINT 5 1 2 Y Y 05/02/2008 11/12/2008 6 100 20 No 
179 M 
02/10/2
006 45 2,7 0 6 1 2 2 1 2 1 1 Y NA NA 1 4 2A 4 0.3 5 1 2 N Y 02/14/2006 10/20/2006 8 200 40 y 
180 M 
11/24/2
009 61 3 0 0.5 1 2 2 1 2 2 0 N N H 1 3 2B 3 2.26 1 1 2 Y N 11/24/2009 11/26/2011 24 100 20 y 
181 F 
05/14/2
010 49 2 0 2 1 2 2 1 3 1 1 Y N H 2 3 3A 3 6.6 2 1 3 Y Y 05/14/2010 12/28/2010 8 100 20 No 
182 M 
10/02/2
007 67 1,3 0 2 1 2 2 2 1 2 1 N NA H 2 3 3B 3 5.55 4 1 2 Y N 10/09/2007 04/22/2008 7 200 40 y 
183 M 
03/23/2
006 42 13 0 2.5 1 2 2 1 1 1 0 N N N 2 3 2A 3 10 1 2 3 Y N 03/31/2006 11/14/2006 8 200 20 No 
184 M 
09/22/2
007 29 2 0 1 2 2 2 2 1 1 1 Y N NA 1 1 3A 2 6 1 1 2 Y Y 09/25/2007 04/01/2008 6 200 40 No 
185 M 
06/17/2
008 40 7 0 3 2 2 2 1 2 1 1 Y H N 1 1 2A 1 2 1 2 1 Y Y 06/24/2008 05/11/2009 11 200 40 No 
186 M 
05/09/2
008 43 2,9 0 5 2 2 2 1 1 1 1 N H NA 1 1 2A 2 5 1 1 3 Y Y 05/09/2008 08/08/2008 3 200 40 No 
187 M 
09/21/2
007 49 1,2 0 4 1 2 2 1 2 2 1 N H N 2 4 3B 4 0.6 1 3 2 Y Y 09/21/2007 06/12/2009 21 100 40 No 
188 F 
11/28/2
006 53 2 0 6 1 1 1 1 1 1 1 Y N NA 1 3 3A 3 4.4 1 1 3 Y Y 12/01/2006 05/01/2008 17 200 40 y 
189 F 
06/08/2
007 55 7,14 1 48 2 2 2 1 2 1 1 Y N N 1 1 1A 1 0.77 4 2 3 Y N 06/08/2007 05/09/2008 11 100 20 y 
190 M 
09/11/
2007 33 1,5 0 1.5 1 1 1 1 2 1 0 N NA NA 1 1 3A 1 3 1 2 3 Y Y 09/18/2007 03/25/2008 6 200 40 No 
191 M 
04/14/2




005 38 2,7 0 9 1 2 2 1 1 1 1 Y N N 1 1 3A 2 3.4 1 2 2 N Y 04/02/2005 11/01/2005 7 200 40 No 
193 M 
04/04/2
010 43 2 0 2 1 2 2 1 1 1 1 N N N 2 3 3A 3 9.4 1 1 3 Y N 04/20/2010 02/11/2011 10 100 40 No 
194 F 
07/26/2
006 49 2 0 2 1 2 2 1 1 1 1 N N NA 1 1 2A 2 0.4 2 2 1 N Y 07/31/2006 12/31/2006 5 200 40 No 
195 M 
01/19/2
010 52 2 0 0.5 2 2 2 1 2 1 1 N N NA 1 1 2A 1 1.5 1 2 3 Y Y 01/19/2010 01/11/2011 12 150 20 No 
196 M 
05/25/2
010 57 14 0 0.5 2 2 2 1 1 1 1 Y NA NA 1 1 2A 1 3.2 1 2 3 Y Y 06/15/2010 12/10/2010 6 100 20 No 
197 M 
08/10/2
006 62 1,2 0 8 1 2 2 2 1 2 0 N NA H 1 4 3B 4 FAINT 5 1 2 Y Y 08/22/2006 06/22/2007 10 200 20 No 
198 M 
12/23/2
005 56 2 0 2 1 2 2 2 1 1 1 N N N 1 2 3A 2 5.1 2 2 2 Y N 01/02/2006 10/28/2006 10 200 40 No 
199 M 
04/16/2
004 72 1 0 4 1 2 2 1 1 1 0 N N N 2 4 3A 4 5 1 1 3 N Y 04/16/2004 09/06/2005 17 400 40 No 
200 M 
10/06/2
006 65 2,14 1 180 2 2 2 1 2 1 1 Y NA NA 1 2 3A 2 3.2 1 2 3 Y Y 10/10/2006 05/04/2007 7 200 40 y 
201 M 
06/23/2
008 50 7,14 0 1 2 2 2 1 2 1 1 Y N NA 1 1 1A 1 3.67 4 2 3 Y Y 06/23/2008 05/30/2009 11 150 20 y 
202 F 
12/23/2
008 47 2 0 3 2 2 2 1 2 1 1 N N NA 1 1 1A 1 1.9 1 2 1 Y Y 01/08/2009 03/19/2010 15 100 20 No 
203 M 
06/26/2
006 64 2,3 0 6 1 2 2 2 2 2 1 N N H 1 4 3B 4 0.49 5 1 2 Y N 07/04/2006 12/31/2006 6 200 40 No 
204 F 
02/16/2
007 68 2,14 0 3 2 2 2 1 2 1 1 Y N NA 1 3 2A 3 3.9 2 1 2 Y Y 02/16/2007 09/18/2007 7 200 40 No 
205 M 
05/09/2
006 62 2,7 0 7 2 2 2 1 2 1 1 N NA N 1 4 2A 4 
BICLO
NAL 6 2 3 Y N 06/02/2006 12/02/2006 6 200 40 No 
206 M 
07/20/2
007 52 2,7, 9 0 6 2 2 2 1 1 1 1 N NA NA 1 1 2A 2 4.58 1 1 1 Y Y 07/20/2007 01/20/2008 6 100 40 No 
207 F 
09/11/
2007 60 1,2 0 12 1 1 2 1 1 1 1 N NA NA 2 3 3A 3 5.2 1 1 3 N Y 09/14/2007 09/12/2008 12 100 40 y 
208 M 
02/06/2
009 48 9 0 1 2 2 2 1 2 1 1 N N H 2 1 2A 1 3.8 1 2 3 Y Y 02/10/2009 09/07/2010 19 150 20 No 
209 M 
06/20/2
008 49 1,2,13 0 8 1 1 2 1 1 1 1 N N H 2 1 3A 2 8.5 1 2 1 Y Y 06/24/2008 04/03/2009 9 200 20 No 
210 F 
01/19/2
007 62 1,2 0 4 1 2 2 1 1 1 1 Y N N 1 3 3A 3 4 1 2 1 Y Y 01/31/2007 01/29/2008 12 100 40 y 
211 M 
07/10/2
007 45 9 1 96 1 2 2 1 1 1 1 Y N N 1 2 3A 2 5 1 1 1 Y Y 07/18/2007 08/22/2008 13 200 40 No 
212 M 
06/09/2
006 64 2 0 18 2 1 2 1 2 2 1 N N N 1 3 2B 3 0 5 1 2 Y Y 06/30/2006 08/07/2007 13 200 20 y 
213 M 
12/05/2
008 54 2 0 36 2 2 2 1 2 1 1 N N N 1 1 1A 1 3.1 1 2 1 Y Y 12/05/2008 12/05/2009 12 100 40 No 
214 M 
05/01/2
007 56 9 0 1 1 2 2 1 1 1 1 N N NA 1 1 3A 2 4.83 4 1 2 Y Y 05/02/2007 07/29/2008 15 150 8 No 
215 F 
04/12/2
006 57 3,11 0 3 1 2 2 2 2 2 1 N N H 2 3 3B 3 0.6 5 1 2 Y N 04/12/2006 06/12/2007 14 200 40 No 
216 M 
07/01/2
007 47 1 0 4 1 2 2 1 1 1 1 N N H 1 1 2A 2 6.25 1 1 2 Y Y 07/13/2007 11/06/2007 4 200 40 No 
217 M 
08/10/2
010 61 2,3 0 2 1 2 2 2 1 2 1 N N NA 2 3 3B 3 8.2 2 3 3 Y N 08/10/2010 05/13/2011 9 200 20 No 
218 F 
02/18/2
006 55 8 0 6 2 2 2 1 2 1 1 N N N 1 1 2A 1 2.91 4 2 3 Y N 02/18/2006 05/18/2006 3 100 20 y 
219 F 
04/08/2
006 35 1,2,8 0 6 1 2 2 1 2 1 1 N N NA 2 3 3A 3 0 5 1 3 Y Y 04/11/2006 03/13/2007 11 200 40 y 
220 M 
07/08/2
005 51 1,2,6 0 6 1 2 2 2 1 1 1 N N H 2 3 3A 3 6.4 1 1 2 Y Y 07/08/2005 12/08/2006 17 200 40 y 
221 M 
01/08/2
006 66 1 0 2 1 2 2 1 1 1 1 N N H 1 3 2A 3 6.9 1 1 2 Y Y 01/08/2006 08/28/2006 8 200 40 No 
222 F 
05/18/2





7 0 12 2 2 2 2 1 1 1 Y N H 1 3 3A 3 2.6 1 2 2 Y Y 06/10/2007 08/19/2008 15 200 40 No 
224 M 
11/14/2
006 51 1,8 0 6 1 2 2 1 2 1 1 N H H 2 1 2A 1 2.8 1 1 2 Y Y 11/20/2006 03/29/2008 17 200 40 No 
225 M 
01/15/2
010 62 2 0 2 2 2 2 1 3 1 1 N NA NA 1 1 3A 4 4.5 1 1 3 Y Y 01/15/2010 09/23/2011 21 100 20 No 
226 F 
10/14/2
008 51 1,2 0 6 1 2 2 1 2 1 1 N N N 1 1 3A 1 5.8 1 1 2 Y Y 10/17/2008 06/02/2009 8 200 40 No 
227 M 
05/12/2
006 53 14 0 1 1 2 2 1 1 1 1 N N N 2 4 2A 4 5.6 1 1 2 Y Y 05/19/2006 04/04/2007 11 200 40 No 
228 M 
02/21/2
006 56 8 0 2 1 2 2 1 2 1 0 N N N 1 4 2A 4 0.6 1 2 2 N N 02/24/2006 05/21/2007 15 200 40 No 
229 F 
06/29/2
009 50 9 0 1 2 2 2 1 2 1 1 Y NA NA 1 1 2A 1 0 5 1 2 Y N 07/07/2009 10/04/2011 27 100 20 No 
230 M 
11/21/2
007 63 3 0 5 2 2 2 1 2 1 0 N NA H 1 1 1A 1 
Dec 
gam 5 1 2 Y N 11/22/2007 02/28/2008 3 200 40 y 
231 M 
07/04/2
008 57 2 0 2 2 2 2 1 2 1 1 N N H 2 3 3A 3 0 5 1 2 Y Y 07/04/2008 12/09/2008 5 200 20 No 
232 M 
05/13/2
008 54 2 0 2 1 2 2 2 1 1 1 N NA N 1 2 3A 2 2.2 2 1 3 Y Y 05/20/2008 07/06/2009 14 150 20 No 
233 M 
02/20/2
007 52 2 0 3 2 2 2 2 2 1 1 Y NA N 1 2 3A 2 4.5 4 1 3 Y Y 02/24/2007 01/04/2008 10 200 20 y 
234 F 
02/26/2
008 50 3 0 3 2 2 2 2 1 2 0 N NA H 1 3 1B 3 2.64 1 1 2 Y N 02/29/2008 06/13/2008 4 200 20 No 
235 M 
04/29/2
008 57 14 0 15 1 2 2 1 2 1 1 Y N N 1 1 2A 2 4.56 1 1 2 Y Y 05/21/2008 01/21/2009 8 200 40 No 
236 M 
08/14/2
008 50 1,2 0 2 2 2 2 1 2 1 0 N N NA 1 3 1A 3 4.23 2 1 2 Y Y 08/29/2008 10/07/2008 1 200 20 No 
237 M 
10/01/2
009 45 2,5 0 3 1 2 2 1 1 1 1 N N N 1 3 3A 3 11.7 1 2 2 Y Y 10/01/2009 12/18/2009 3 100 20 No 
238 F 
07/16/2
008 40 2 0 2 1 2 2 1 2 1 1 N N N 1 2 3A 2 3.2 1 2 3 Y Y 08/05/2008 05/22/2009 10 200 20 No 
239 F 
07/05/2




010 51 1,8,13 0 3 1 2 2 1 1 1 0 N N H 1 3 3A 3 9.2 1 2 1 y y 04/13/2010 07/23/2010 3 200 20 No 
241 M 
05/21/2
010 52 2,3 0 1 1 2 2 1 1 2 1 N N H 1 3 3B 3 3.79 1 1 3 Y Y 05/21/2010 09/07/2010 4 100 20 No 
242 M 
11/23/2
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O 0 na na na na na na na na na na na na na na na na na na na 








11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 1 3 PR 1 12 1 PD 2 
04/20/20
07 CP c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 








11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




10 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 












O 0 na na na na na na na na na na na na na na na na na na na 
0 0 3 PR 1 6 1 PR 1 
09/03/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 
VGP
R 1 21 NA PD 1 
04/18/20
09 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 






12 na a na na na 
N
O 1 6 CR 1 
20
0 3 5.7 17 11 11 11 4 7 16 VGPR N 
01/05/
2012 0 16  
0 7 4 CRu 0 
N
A NA CRu 1 
12/14/20
07 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 
VGP
R 1 13 2 PD 2 
03/10/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 
VGP




11 CP c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 5 
VGP




11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 1 5 
VGP
R 1 7 2 CRu 1 
08/05/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 5 PR 1 6 2 PD 2 
09/21/20
09 LLD c na na na y 0 na na na na na na na na na na na na na na na na na na na 
1 5 5 PR 1 31 1 PD 2 
01/25/20
08 CD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 5 
VGP
R 1 22 1 PD 1 
12/02/20
08 CP c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 5 PR 1 7 1 PR 1 
09/20/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 5 
VGP








O 0 na na na na na na na na na na na na na na na na na na na 
0 1 5 CRu 1 38 1 PD 2 
12/02/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 0 5 PR 0 
N
A NA PR 1 
09/16/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 0 3 PR 1 53 1 PD 1 
11/08/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 5 PR 0 
N
A NA CR 1 
12/28/20
11 na a na na na 
N




0 3 5.4 9.9 10 11 11 5 1 5 CR N 
12/28/
2011 1 6 100 








O 0 na na na na na na na na na na na na na na na na na na na 
1 0 5 PR 0 
N
A NA PR 1 
08/16/20
11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




A NA CRu 1 
11/03/20
11 CTD a na na na 
N




0 1 4.9 3 11 11 13 8 1 13 VGPR N 
11/03/
2011 2 7 na 
0 0 5 PR 1 13 NA PD 1 
07/15/20
09 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 1 3 
VGP
R 1 10 1 PD 2 
09/18/20
09 CTD c na na na 
N






5 11 11 12 8 16 21 VGPR Y 
10/15/
2008 1 11 100 
0 0 5 PR 0 
N
A NA PR 1 
10/29/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 0 3 
VGP
R 1 48 1 PD 2 
01/18/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




11 LLD na na na na 
N








5 12 13 14 8 2 12 VGPR N 
11/24/
2011 1 8 100 
0 0 na NR 1 0 1 PD 2 
08/08/20
08 MP na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




10 CD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 3 
VGP
R 1 43 1 PR 1 
12/19/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 0 6 PR 1 33 2 PD 2 
01/22/20
11 PAD a na na na 
N
O 1 16 PR 2 
14
0 2 7.3 
3.0
3 12 12 12 6 3 16 VGPR Y 
06/14/
2010 2 16 na 
0 0 3 
VGP
R 1 6 1 PD 2 
10/19/20
09 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 6 PR 1 6 1 PR 1 
12/16/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
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0 0 3 
VGP
R 1 11 1 PD 2 
10/06/20
09 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 6 PR 1 6 1 PR 1 
09/30/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 3 
VGP
R 1 13 1 PR 1 
08/14/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 0 6 PR 1 6 1 PD 1 
06/09/20






8 6.3 10 10 10 6 2 7 VGPR Y 
1/7/20
08 1 9 100 
0 0 3 PR 1 20 1 PR 1 
11/11/20
08 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




11 PAD na na na na 
N






7 11 11 12 5 1 8 CRu N 
07/18/
2011 0 0  
0 0 na NR 1 0 1 CR 1 
09/06/20
11 PAD na na na na 
N






5 12 12 12 5 6 12 CRu N 
09/06/
2011 0 0  
0 0 na NR 1 0 1 PD 1 
12/20/20
11 PAD na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 6 PR 1 11 1 PD 1 
09/14/20
11 CTD c na na na 
N




0 3 6.1 
2.6
8 12 12 21 7 3 10 PR Y 
09/14/
2011 0 0  




10 LD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 








O 0 na na na na na na na na na na na na na na na na na na na 
0 0 3 PR 1 6 1 PR 1 
09/23/20
11 MPT c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 6 PR 1 36 1 PD 2 
11/28/20
08 CTD c na na na 
N









F LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT









U LTF LTF 
LT
F LTF na na na na na 
LT
F LTF na na na na na na na na na na na na na na na na na na na 
0 1 na NR 1 0 NA PD 2 06/10/20 na na na na na N 0 na na na na na na na na na na na na na na na na na na na 
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09 O 
0 0 na NR 1 0 NA PD 2 
03/07/20
08 na na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 na NR 1 0 NA PD 1 
09/27/20
11 na na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 na NR 1 0 NA PD 1 
12/22/20
09 na na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 na NR 1 0 NA PD 1 
08/17/20
10 na na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 3 
VGP
R 1 14 1 PD 1 
07/03/20
09 MPT c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 6 PR 0 
N
A NA PR 1 
03/27/20
08 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 3 
VGP
R 1 8 1 CRu 1 
07/22/20
08 PAD b 10/23/2007 
03/25/200
8 100 y 0 na na na na na na na na na na na na na na na na na na na 
0 0 6 PR 0 
N
A NA PR 1 
09/05/20
11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 3 PR 0 
N
A NA PR 1 
07/12/20
11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 












O 0 na na na na na na na na na na na na na na na na na na na 
1 0 3 PR 0 
N
A NA PR 1 
11/08/20
11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 








06 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 1 3 PR 0 
N
A NA PR 1 
09/07/20
10 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 












O 0 na na na na na na na na na na na na na na na na na na na 
0 1 3 PR 0 
N
A NA PR 1 
12/07/20
11 na a na na na 
N






8 12 12 11 7 5 12 PR N 
12/07/
2011 1 29 100 












O 0 na na na na na na na na na na na na na na na na na na na 








O 0 na na na na na na na na na na na na na na na na na na na 
1 5 7 PR 1 12 3 PR 1 
01/24/20




O 0 na na na na na na na na na na na na na na na na na na na 








11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 7 PR 1 8 1 PR 1 
08/06/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 








07 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 7 PR 1 7 1 CRu 1 
03/06/20
07 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 








06 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 7 PR 1 50 1 PR 1 
06/21/20




O 0 na na na na na na na na na na na na na na na na na na na 




A NA CR 1 
11/10/20
11 na a na na na 
N




0 3 6.9 
4.4
8 11 12 11 8 3 6 CR N 
11/10/
2011 0 0  








11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




A NA PR 1 
12/16/20
11 na a na na na 
N




0 4 4.7 
8.5
4 12 12 12 6 4 14 VGPR N 
12/16/
2011 0 0  




A NA CR 1 
12/05/20
11 na a na na na 
N






2 3.8 12 12 11 5 3 13 CR N 
12/05/
2011 0 0  








11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 








11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 












O 0 na na na na na na na na na na na na na na na na na na na 
0 0 7 
VGP
R 1 33 NA PR 1 
08/30/20
11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 








11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 8 
VGP
R 1 22 2 PD 1 
11/25/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




A NA CR 1 
11/18/20
08 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




07 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




A NA CR 1 
12/16/20
11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 8 
VGP
R 1 10 1 PD 2 
09/21/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
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08 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 










O 0 na na na na na na na na na na na na na na na na na na na 








08 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




A NA CRu 1 
09/04/20
09 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 












O 0 na na na na na na na na na na na na na na na na na na na 




A NA CR 1 
06/12/20
09 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 3 CR 0 
N
A NA CR 1 
08/09/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 1 9 CR 1 51 1 PD 1 
01/03/20
12 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 










O 0 na na na na na na na na na na na na na na na na na na na 
0 0 9 
VGP
R 1 28 1 PD 1 
07/29/20
11 TD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 3 CR 0 
N
A NA CRu 1 
02/22/20
11 na a na na na 
N
O 1 4 CR 1 
20
0 3 3.8 
5.6
6 10 10 11 8 4 9 CR N 
02/22/
2011 0 0  




11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 3 CR 0 
N
A NA CRu 1 
02/04/20
10 na a na na na 
N






8 13 13 14 6 7 11 CRu N 
02/04/
2010 1 31 100 
0 0 10 PR 1 12 1 PR 1 
11/15/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 0 3 CRu 0 
N
A NA CRu 1 
11/04/20




O 0 na na na na na na na na na na na na na na na na na na na 








O 0 na na na na na na na na na na na na na na na na na na na 
1 0 3 CRu 0 
N
A NA CRu 1 
08/04/20




O 0 na na na na na na na na na na na na na na na na na na na 
1 0 11 PR 1 29 1 PD 1 
02/25/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 1 3 CRu 0 
N
A NA CRu 1 
07/26/20




O 0 na na na na na na na na na na na na na na na na na na na 
1 0 11 PR 1 23 1 PR 1 
08/04/20




O 0 na na na na na na na na na na na na na na na na na na na 
1 0 3 CRu 0 
N
A NA CR 1 
12/20/20
11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 11 PR 0 
N
A NA PR 1 
06/12/20
07 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 3 
VGP
R 1 16 1 PD 2 
05/30/20




O 0 na na na na na na na na na na na na na na na na na na na 








08 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 3 
VGP
R 1 47 1 PD 1 
06/10/20
11 TD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 12 PR 1 12 1 PR 1 
07/15/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 PR 1 19 2 PD 1 
11/30/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 PR 1 23 2 PD 2 
10/11/20
09 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 1 13 
VGP








O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 PR 1 13 2 PD 2 
03/09/20
10 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 13 PR 1 25 1 PD 2 
10/15/20
10 MPT c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 1 4 PR 1 15 2 PR 1 
04/16/20
10 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 13 PR 0 
N
A NA PR 1 
06/12/20
07 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 1 4 PR 1 4 2 PR 1 
07/17/20
08 LD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 








11 na c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 PR 1 46 2 PR 1 
11/17/20
11 MP c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 PR 1 11 3 PD 1 
06/21/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 PR 1 14 3 PR 1 12/23/20 CTD c na na na N 1 9 PR 3 20 4 8.1 9.1 10 10 11 6 2 16 PR Y 10/4/2 1 24 100 
 110 
 111 
11 O 0 010 
0 0 4 PR 1 14 3 PD 2 
01/17/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 4 4 
VGP
R 1 27 3 PR 1 
09/02/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 
VGP
R 1 11 3 PD 2 
03/23/20
10 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 
VGP
R 1 51 3 PD 2 
11/27/20
11 TD a na na na 
N
O 1 15 PR 1 
20
0 2 8 7.2 11 11 8 5 5 11 Cru Y 
02/01/
2011 1 10 200 
0 0 4 CRu 1 21 1 PD 1 
09/25/20
11 CP c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 PR 1 11 1 PD 1 
04/05/20
07 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 PR 1 47 1 PD 2 
12/17/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 1 4 PR 1 27 1 PR 1 
10/04/20
11 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 na NR 1 0 2 PD 1 
05/15/20
09 CP na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 5 na PD 1 0 2 PR 1 
11/04/20
11 CP na na na na y 0 na na na na na na na na na na na na na na na na na na na 
0 0 4 
VGP




09 CTD c na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 4 
VGP
R 1 25 1 PD 1 
03/24/20




O 0 na na na na na na na na na na na na na na na na na na na 
0 1 na MR 1 0 2 PR 1 
05/10/20
11 CTD na na na na y 0 na na na na na na na na na na na na na na na na na na na 
1 0 na MR 1 0 2 PD 2 
09/29/20
09 CTD na na na na y 0 na na na na na na na na na na na na na na na na na na na 




11 CTD na na na na 
N








1 10 10 9 4 1 5 CRu N 
09/29/
2011 2 7 na 
0 0 na NR 1 0 2 PR 1 
12/27/20
11 CTD na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 




11 CTD na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
1 0 na NR 1 0 2 PD 2 
07/17/20
07 CTD na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 na NR 1 0 2 PD 2 
10/26/20
10 CTD na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 na NR 1 0 2 PD 1 
05/20/20
11 CTD na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
0 0 na NR 1 0 2 PR 1 
01/09/20
12 CTD na na na na 
N
O 0 na na na na na na na na na na na na na na na na na na na 
 
 
 
 
